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Background Key populations such as people who inject drugs (PWID) lag behind in the 
UNAIDS 90-90-90 target, particularly at diagnosis. Respondent-driven sampling (RDS), a 
referral method that leverages peer network connections, is widely used in HIV surveillance and 
research for sampling hidden populations. The objective of this dissertation is to inform the 
utility and implementation of a strategy using RDS that seeks to improve levels diagnosis among 
HIV-infected PWID in India. 
 
Methods First, we assessed the ability of RDS to reach undiagnosed HIV-infected PWID and 
other sub-populations compared to a venue-based strategy (integrated care centers [ICCs]). Next, 
we explored recruiter characteristics associated with recruiting undiagnosed HIV-infected PWID 
into an RDS sample and identified settings these characteristics predicted best. Lastly, we 
evaluated whether the efficiency of identification of undiagnosed HIV-infected PWID can be 
enhanced through alterations to the RDS coupon system. 
 
Results RDS required screening fewer PWID and more rapidly identified undiagnosed HIV-
infected PWID compared to ICCs. The number needed to recruit (NNR) - average number of 
PWID recruited/screened in order to find one undiagnosed HIV-infected PWID - for the ICC was 
26 and for RDS was 11. HIV/HCV infection and factors associated with higher HIV risk were 
most strongly associated with recruiting an undiagnosed and viremic person who injects drugs 
living with HIV (PLWH). The prediction model performed best in areas with low harm reduction 
access and for recruiting an undiagnosed PLWH, prediction was best in settings with low 
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HIV/HCV services and high HIV incidence. The altered RDS coupon system in which 
individuals more likely to recruit undiagnosed HIV-infected PWID were provided more 
recruitment coupons did not significantly improve the efficiency of identification of undiagnosed 
PWID over the normal/traditional coupon system in which all participants receive the same 
number of coupons (NNRnormal=16.4 vs. NNRaltered=12.5; difference=3.9, 95% CI: -1.6 to 13.1). 
 
Conclusion Reaching the UNAIDS 90-90-90 target requires using existing evidence-based 
prevention and care interventions but also finding new strategies to make marked progress in the 
care continuum. These findings highlight a potentially promising way to close the gap for PWID 
at diagnosis by utilizing RDS beyond its traditional sampling purpose. 
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Chapter 1: Introduction 
BACKGROUND 
Global HIV epidemic 
Since the peak of the HIV epidemic in the mid 1990’s, there have been great strides made in 
slowing the global HIV epidemic. New infections have almost been halved and access to life-
saving treatment has drastically improved, especially in the last decade, leading to decreased 
HIV/AIDS-related mortality. Despite these improvements, there were approximately 1.8 million 
people newly infected with HIV in 2017. In total, there are nearly 37 million people living with 
HIV and over 900,000 died of AIDS-related illnesses in 20171. The largest burden of disease 
continues to be seen in eastern and southern Africa. However, this region also has some of the 
highest treatment coverage, resulting in recent sharp declines in new HIV infections among 
adults, compared to other regions such as Asia and the Pacific that have seen static trends in new 
infections and eastern Europe and central Asia where new infections increased 57% since 20102.  
 
90-90-90 target 
In 2014, UNAIDS set an ambitious target of 90-90-90 by 2020 to help end the global AIDS 
epidemic3. The goal is that 90% of those HIV-infected will be aware of their diagnosis; 90% of 
those diagnosed will be linked to clinical care and on sustained antiretroviral therapy (ART) and, 
ultimately, 90% of those on ART will achieve viral suppression. Fueled by the recognized 
individual and community benefits of expanded ART access and use, this new global approach 
promotes successful progression through all the steps of the HIV care continuum, which 
documents population levels of HIV diagnosis to viral suppression4. For individuals, initiation of 
and adherence to ART significantly slows clinical progression, reducing AIDS-associated 
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morbidity and mortality5-7. Additionally, early initiation of ART leads to reduced circulation of 
the virus which reduces the rate of transmission to sexual partners8. At a community-level, 
higher levels of ART coverage among populations has been shown to lead to decreased viral 
load in the community and a decrease in the number of new HIV infections9,10. The 90-90-90 
target also prioritizes equity for all those affected by HIV, including key populations such as 
people who inject drugs (PWID), based on principles of human rights with continued efforts to 
eliminate stigma, discrimination, and social exclusion. 
 
HIV epidemic in India 
In 1986, Dr. Suniti Solomon along with her student, Sellappan Nirmala, were the first to find 
evidence of HIV in India after collecting samples from several female sex workers in Chennai, 
Tamil Nadu, in south India11. Like many other areas of the world, HIV continued to rise 
throughout the 1990’s in India, with key populations - female sex workers, men who have sex 
with men (MSM), transgender individuals, and PWID being the hardest hit12. India continues to 
experience a concentrated HIV epidemic and has the third largest population of people living 
with HIV (PLHIV) and third largest number of AIDS deaths globally, only after South Africa 
and Nigeria12. 
 
Injection drug use is a major driver of established and new HIV epidemics in many low- and 
middle-income countries (LMICs)13-15, including India, where there are an estimated 1.1 million 
PWID16. Transmission of HIV in injecting populations is largely due to sharing used injection 
paraphernalia (e.g., needles and syringes) with others, with a high estimated per-act probability 
of transmission17. Many PWID in India are impoverished and often experience social 
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marginalization and discrimination, making them less likely to seek HIV prevention services and 
care for HIV, drug treatment, or other health issues18-21. India, similar to other LMICs, has made 
dramatic progress in the delivery of HIV prevention and treatment services to the general 
population. Consequently, overall reductions in HIV prevalence and incidence have been 
observed22. However, key populations including PWID continue to have a high burden of HIV 
infection. The National AIDS Control Organisation (NACO), India estimates 6%22 of PWID are 
HIV-infected, while we previously found a prevalence of 18% with significant variation across 
cities and regions23. This is in stark comparison to a 0.3% prevalence among the general 
population24.  
 
The HIV care continuum illustrates that the largest gap for PWID in India occurs at diagnosis, 
with only 43% being aware of their positive status (Figure 1.1)25. Significant attrition also 
occurs at the linkage to care and treatment initiation steps. HIV-infected PWID unaware of their 
status and/or not engaged in medical care are likely to have high viral loads, which in addition to 
putting their own health at risk, results in a higher likelihood of transmission of HIV to those 
with whom they share injecting paraphernalia and to sexual partners26-28. Since many PWID are 
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not self-referring for HIV testing and clinical care or sufficiently engaged by traditional outreach, 
additional strategies are needed to increase the number of diagnosed HIV-infected PWID and to 
achieve the UNAIDS 90-90-90 target. This would in turn lead to increased ART coverage, 
decreased community viral load, and, ultimately, fewer new infections9,10,27,29,30. 
 
Peer-based interventions 
Extensive research on social networks and health has demonstrated the importance of looking 
beyond the individual31-33. Among PWID, the peer network structure and norms and 
characteristics of those in the network are predictive of high-risk behaviors such as unprotected 
sex and sharing injecting paraphernalia as well as HIV and hepatitis C virus (HCV) infection34-41. 
Among a cohort of male PWID in Chennai, prevalent HIV and HCV were associated with 
material support provided by network members and HCV infection was associated with having 
long-term active drug using network members and drug using network members being male 
kin42. Given the significant influence of networks on health and health behaviors, many have 
turned to using social networks to deliver interventions.  
 
Specifically in HIV, peer driven interventions or other approaches that utilize networks to 
disseminate HIV prevention education through networks of PWID have been successful at 
decreasing risky behaviors43-48. In addition to interventions centered on HIV prevention, a few 
studies have also explored how to use peers to reach those who are HIV-infected yet unaware 
and hence undiagnosed49-52. These approaches were generally more effective at identifying new 
cases of HIV as compared to other strategies such as venue-based testing or self-referral; 
however, the majority of these studies were among MSM in urban areas in the United States53-56. 
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The utilization of social networks to improve HIV care continuum outcomes among PWID or 
other people who use substances is not well characterized57. 
 
Respondent-driven sampling 
 Respondent-driven sampling (RDS), a chain referral method that leverages peer network 
connections, is now widely used in public health research, especially for HIV, for sampling 
hidden or difficult-to-reach populations such as PWID, MSM, and sex workers - groups for 
which no sampling frame exists58,59. Sampling begins with seeds, generally 2-10, who are 
influential and well-connected members of the target population. Each seed receives recruitment 
coupons, normally 2-5, to distribute to network members at random. Persons given coupons 
return to the study center with the coupon and, if eligible, are enrolled and administered a survey 
and complete other study procedures - this constitutes a recruitment wave. Seeds are considered 
wave 0, their recruits wave 1, and so on. Recruits are also given recruitment coupons to 
distribute to their network (Figure 1.2). If recruitment is too slow or too rapid, the number of 
recruitment coupons provided may be changed. There is dual compensation for RDS study 
participation. Study participants are provided money for participating in the study and for each 
 6 
eligible person they recruit into the study. This iterative procedure continues until the desired 
sample size is reached (Figure 1.3).  
 
It should be noted that there are limitations to the RDS method and some assumptions underlying 
estimators for population characteristics are unlikely to be satisfied and/or difficult to assess60-63. 
New estimators for RDS data are an active area of research with newer estimators addressing 
common violation to assumptions.  However, given appropriate conditions and after analytical 
correction for the sampling method, RDS can provide unbiased population estimates such as risk 
factors and disease burden (e.g., HIV prevalence)58,64.  
 
For the purposes of surveillance, RDS has proved to be an efficient strategy to recruit PWID in 
India, generally a more difficult population to sample given the illegal and stigmatizing nature of 
injection drug use. Specifically, our previous work has highlighted that RDS was able to reach 
undiagnosed and viremic HIV-infected PWID that had not previously been successfully engaged 
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by other means65 and thus has the potential to be used as part of a service delivery model for 
PWID in LMICs.  
 
GAPS IN KNOWLEDGE 
Most researchers use RDS for the purposes of routine serologic and behavioral surveillance in 
populations for which no sampling frame exists. Recently, however, investigators have noted the 
promise of RDS as an implementation tool for vulnerable populations such as MSM and 
PWID66-69. Several prior RDS studies have found that PLHIV are more likely to recruit other 
PLHIV into an RDS50,70 and that HIV-related characteristics (e.g., HIV testing history and 
diagnosis) change as recruitment progresses over time66,71. Therefore, the RDS recruitment 
process could be leveraged for the basis of an intervention in certain difficult to reach sub-groups 
within key populations, such as those undiagnosed and/or viremic (i.e., detectable viral load). 
Comparisons of RDS to traditional venue-based strategies and how best to alter this system of 
chain-referral to improve the identification of undiagnosed HIV-infected PWID is largely 
unknown, especially in the context of LMICs. Others have attempted to steer RDS recruitment to 
sub-groups such as younger or higher-risk PWID in the United States by increasing financial 
reimbursements; however, these approaches were met with mixed success72,73. Capitalizing on 
what is known about recruiters and their recruits as well other recruitment patterns provides a 






SPECIFIC AIMS AND HYPOTHESES 
This research will inform the utility and implementation of an intervention strategy using RDS 
that seeks to improve levels of diagnosis among HIV-infected PWID. Specific aims of this 
dissertation are: 
 
Aim 1: To assess the ability of RDS to reach key sub-populations of PWID (e.g., by HIV 
infection, diagnosis status, and socio-demographics) as compared to a venue-based strategy 
(integrated care centers [ICCs]). 
Regression models will identify individual characteristics associated with being identified by the 
RDS versus an ICC. Additionally, the overall ability of RDS and ICCs to reach undiagnosed 
HIV-infected PWID will be summarized using the number needed to recruit (NNR). The NNR is 
the average number of PWID that are recruited/screened in order to find one undiagnosed HIV-
infected PWID. The lower the NNR, the more efficient the strategy. 
Hypothesis 1: RDS will have a lower NNR for undiagnosed PWID compared to ICCs. 
 
Aim 2: To identify individual recruiter characteristics associated with identification of 
PWID via RDS who are HIV-infected and undiagnosed or viremic and identify in which 
settings these characteristics predict recruitment best. 
Prediction models will be built to discriminate between those that do and do not recruit 
undiagnosed/viremic HIV infected PWID into an RDS. Areas under the receiver operating curve 
(AUROC) will be used to evaluate single and combinations of characteristics. 
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Hypothesis 2: Recruiter characteristics that will best predict identification of an 
undiagnosed HIV-infected PWID include: positive HIV status, daily drug injection, and a 
larger network size. 
 
Aim 3: To evaluate whether the efficiency of identification of undiagnosed HIV-infected 
PWID can be enhanced through alterations to the RDS coupon system. 
Alterations to the RDS coupon system will be evaluated in Morinda, Punjab. Specific alterations 
will include providing more recruitment coupons to HIV-infected PWID as compared to HIV-
negative PWID; other potential recruiter characteristics that warrant additional coupons will be 
identified in Aim 2. Two seeds will initiate recruitment; starting at wave 1, study participants 
will be randomized individually in a 1:1 allocation to the normal RDS coupon system - in which 
all participants regardless of characteristics receive the same number of recruitment coupons - or 
the altered system. The number needed to recruit (NNR) for undiagnosed HIV-infected PWID 
will be compared between recruits of the two coupons systems.  
Hypothesis 3: The altered RDS approach will have a lower NNR for undiagnosed HIV-
infected PWID compared to the normal RDS approach. 
 
Data sources 
This dissertation capitalizes on a large existing RDS dataset from India. Aim 1 and Aim 2 use 
data collected as part of a cluster-randomized trial, the National Collaboration on AIDS (NCA) 
trial74. For the baseline assessment, 15 PWID cities were included, representing 4 different stages 
of injection drug use (Figure 1.4). The Northeast (Aizawl, Churachandpur, Dimapur, Gangtok, 
Imphal, Ludhiana, Moreh) has the oldest, established epidemic largely due to its proximity to the 
 10 
opium producing area, the ‘Golden Triangle’75. A more recent emerging injection drug use 
epidemic has been documented in the North (Amritsar, Chandigarh, and Ludhiana) while little 
prior data exists on injection drug use in Central India (Bhubaneswar, Bilaspur, and Kanpur). 
Injection drug use has been observed in the large cities of Mumbai and New Delhi over the past 
two to three decades.  
 
Baseline and evaluation cross-sectional assessments used RDS to recruit PWID study 
participants (1000 per city). For the trial, 12 cities were selected (Bhubaneshwar, Gangtok, and 
Moreh were dropped) and randomized to a 1:1 allocation ratio. After the baseline assessment and 
randomization, ICCs - the intervention being tested - were scaled up in the six intervention cities 
and ran for approximately two years before initiating the evaluation RDS assessment. 
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Aim 3 is nested within the Reaching the Hardest of the Hard-to-reach (RHR) study, which is 
exploring the cost-effectiveness of RDS-based strategies at identifying PWID.  One strategy 
being tested is the targeted time-based RDS (ttRDS), in which an RDS will run for at least one 
year and is evaluating the impact of varying the number of coupons for recruitment. This strategy 
is the focus of Aim 3 and is being conducted in Morinda, Punjab, located on the main road 
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Background Injection drug use drives HIV epidemics in many low-resource settings. Many 
people who inject drugs (PWID) are inadequately engaged in HIV services, resulting in low 
awareness among HIV-infected PWID. Respondent-driven sampling (RDS), a method using peer 
connections, is widely used in research among key populations. This study assesses the ability of 
RDS to identify undiagnosed HIV-infected PWID compared to a venue-based strategy in India. 
 
Methods In six Indian cities from 2014-2017, integrated care centers (ICCs) provided PWID-
tailored services such as HIV counseling/testing and needle exchange. In these same cities from 
2016-2017, an RDS sample of 1000 PWID/city was conducted; RDS participants were 
compensated for time and referrals. Undiagnosed individuals were those who tested positive and 
denied a prior diagnosis. The number needed to recruit (NNR) (number screened in order to find 
one undiagnosed HIV-infected PWID) and the identification rate (number of undiagnosed PWID 
identified per week) assessed the efficiency of RDS vs. ICCs. Multinomial logistic regression 
was used to explore characteristics associated with identification by RDS only and RDS & ICC, 
both in comparison to ICC only.  
 
Results Across the six cities, there were 10,759 ICC clients and 6,012 RDS participants; 40% of 
RDS participants were ICC clients (confirmed via biometrics) resulting in 14,397 unduplicated 
PWID, of which 753 (5%) were undiagnosed. Overall, the RDS NNR was 11 and ranged from 5 
to 27 across the cities. The overall ICC NNR was 26 and ranged from 10 to 74. The NNR was 
lower for RDS versus the ICC overall and in all but one city. The RDS identification rate 
(overall: 18.6/week; cities: 1.7 to 2.8/week) was faster than the ICC identification rate (overall: 
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2.7/week; cities: 0.2 to 1.0/week) overall and in all cities. PWID identified by RDS vs. the ICC 
only were more likely to be male (adjusted odds ratios [aOR] RDS only: 6.8, both: 2.7) and HIV-
infected but undiagnosed (aOR RDS only: 2.5, both: 1.5).  
 
Conclusions In India, RDS required screening fewer PWID and more rapidly identified 
undiagnosed HIV-infected PWID as compared to ICCs. Network-driven recruitment strategies 
with moderate compensation could be considered to identify and engage groups of PWID not 




Injection drug use continues to be a driver of HIV epidemics in many settings, including low- 
and middle-income countries. Globally, injection drug use accounts for 30% of new infections 
outside of sub-Saharan Africa1 and currently accounts for some of the fastest growing HIV 
epidemics globally2. In India, there are an estimated 1.1 million people who inject drugs3, with 
growing injection drug use and HIV epidemics observed in new regions4. HIV prevalence in 
India is relatively low among the general population (0.26%5) while PWID experience a 
disproportionate burden - 6.3% being HIV-infected6, with significant regional variation in 
prevalence7.   
 
In order to end the global HIV epidemic, UNAIDS has set the 90-90-90 target by 2020 - 90% of 
those HIV-infected diagnosed, 90% of those diagnosed linked to care and on sustained 
antiretroviral therapy (ART), and 90% of those on ART virally suppressed8. Importantly, these 
targets prioritize equity for all those effected by HIV, including key populations such as PWID 
who often lag behind in terms of the HIV care continuum9. HIV testing, medical care, and ART 
are provided free-of-charge by the government of India; however, utilization of services remains 
sub-optimal for populations like PWID due to stigma, discrimination, and accessibility10. We 
previously estimated approximately 40% of HIV-infected PWID were diagnosed11 - well behind 
the UNAIDS 90% diagnosis target. 
 
Therefore, there is an urgent need for novel strategies to reach undiagnosed HIV-infected PWID 
and efficiently link them to HIV testing and care services. Venue-based strategies such as testing 
centers and drop-in centers are frequently used to reach high-risk, stigmatized groups such as 
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men who have sex with men (MSM), sex workers, and PWID, and are often staffed by members 
of the target population and provide a safe place to deliver a variety of HIV prevention and care 
services specific for that population such as HIV/STI testing or referrals for appropriate testing 
and medical care, condoms, counseling, peer support and education. Social network-driven 
strategies have also been shown to be effective in reaching and engaging populations for HIV 
testing. Using peers to diffuse HIV prevention messages within a social network in order to 
change behavioral norms and reduce HIV risk has been found effective12. However, among 
PWID and other substance using populations, using social networks beyond HIV prevention, to 
improve steps in the HIV care continuum, has not been well-characterized13 with few 
comparisons to traditional venue-based strategies. 
 
Respondent-driven sampling (RDS) is a commonly used approach in public health for HIV 
surveillance and other research purposes that leverages peer network connections to sample 
hidden or difficult-to-reach populations such as MSM and PWID, groups for which no sampling 
frame exists14. Given a set of assumptions, estimators can be used to calculate population 
estimates such as HIV prevalence from the resulting sample15, which is most often the goal of 
the RDS. Recently however, several studies have described the potential of using RDS or similar 
network-based strategies to reach those with undiagnosed, untreated, or new HIV infection16-19. 
This study assesses the ability of RDS to identify undiagnosed HIV-infected PWID compared to 
a venue-based strategy in India. 
 
METHODS 
Study design and procedures 
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Data for this study were collected for the National Collaboration on AIDS (NCA) trial 
(ClinicalTrials.gov identifier: NCT01686750), a cluster-randomized trial among MSM and 
PWID in India investigating the effectiveness of integrated care centers (ICCs) on the 
community uptake of HIV testing20. Data are restricted to the PWID stratum of the trial for this 
analysis. Effectiveness of the ICCs was assessed using two serial community-based cross-
sectional samples before (baseline) and at least two years after implementation of ICCs 
(evaluation), which were established in 6 cities in India (six other cities acted as control cities for 
the PWID stratum of the trial). For this analysis, we utilized ICC client data from the six cities 
with ICCs and the evaluation RDS data from the same six cities. Three of the cities were located 
in the northeast of India (Aizawl, Dimapur, and Imphal), two in the north (Chandigarh and 
Ludhiana), and one in central India (Bilaspur). 
 
ICCs were scaled-up and established in each city between April-July 2014 and provided PWID-
focused services for approximately 2.5 years, until November 2016-February 2017. The number 
of ICCs established in each city was dependent on geography and the estimated size of the PWID 
population. One ICC was used in Aizawl, Dimapur, and Ludhiana, two were established in 
Bilaspur and Chandigarh (both later consolidated into one location), and three were established 
in Imphal. Services provided at the ICCs included HIV counseling and testing (HCT), hepatitis C 
antibody testing (excluding Chandigarh), syringe services (SSP), opioid agonist therapy (OAT), 
syndromic screening and treatment for sexually transmitted infections (STIs), condoms, 
tuberculosis screening, medical care and refills of antiretroviral therapy (ART) for HIV-infected 
clients, counseling on risk reduction (i.e., safe sex and injecting behaviors), other general health 
services such as blood pressure and glucose checks, and appropriate referrals. Service utilization 
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was voluntary and clients were not compensated for HCT or any other service utilization. A 
nurse and counselor were available onsite every day and a part-time physician was available on-
site. Peer outreach workers encouraged PWID in the community to visit the ICC and tracked 
clients that needed to return for services such as a repeat HIV test. A biometric system was used 
to track unique clients receiving services at the ICC, the services they used, and their lab results. 
Clients’ fingerprints were scanned then converted into unique alphanumeric codes using 
proprietary software; codes could not be converted back to fingerprint images. General 
demographics (e.g., gender, marital status, education, pin code of residence) were collected from 
ICC clients when they registered at their first visit. HIV testing history, risk behaviors, and 
diagnosis were recorded at the time of HCT. In accordance with Indian guidelines, HIV infection 
was assessed on-site using 3 rapid tests: Alere Deterimine 1/2 (Alere Medical, Chiba, Japan), 
First Response HIV Card Test 1-2.0 (Premier Medical Corporation, Daman, India), and Signal 
Flow Through HIV 1+2 Spot/Immunodot Test Kit (Span Diagnostics, Surat, India). Those found 
positive were case managed using peer health workers; more details on ICC service delivery can 
be found in the trial protocol paper20.  
 
The evaluation assessment was conducted using RDS in each of the six cities from August 2016-
February 2017. Two seeds - well-connected and influential PWID in the community - were used 
to initiate recruitment in each city. All seeds and subsequent study participants (i.e., recruits) 
were given two recruitment coupons to distribute to others they knew in the community that 
inject drugs. Individuals that received a coupon returned to the study center, if eligible, enrolled 
in the study, completed study procedures, and received two recruitment coupons to distribute to 
their network at random. Coupons had a bar-code to link recruiters and recruits as well as a 
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hologram to prevent duplication. Recruitment continued until the desired sample size was met - 
1000 in each city. Eligibility criteria to enroll in the RDS included (1) being at least 18 years old, 
(2) provision of informed consent, (3) possession of a valid coupon unless a seed, and (4) self-
reported injection drug use in the prior 24 months. Compensation was provided for study 
participation (US $3.8 [INR 250]) and for each recruit participants referred that enrolled in the 
study (US $0.80 [INR 50]/recruit, up to two total). The same biometric system was used to track 
duplicate enrollment of participants and to link study participants that were also ICC clients. 
After informed consent, RDS participants provided a blood sample and completed an 
interviewer-administered questionnaire with modules on socio-demographics, network 
characteristics, injection and sexual risk behaviors, harm reduction service use, and HIV testing 
and care history. All participants underwent HIV counseling and testing using 3 rapid tests (as 
described previously in the ICCs) with appropriate referrals for medical care for those that tested 
positive. Importantly, all RDS procedures were carried out at a discrete study venue that was not 
associated with the ICC.  
 
Statistical methods 
The main outcome of interest is the approach that identified PWID from the community - the 
ICC or RDS. For exploratory data analysis and regression modeling, a pooled data set was 
created containing ICC client data from the six cities and the evaluation RDS sample from these 
same cities. Using the biometric data, we classified individuals in the pooled data as being 
identified by the ICC only (i.e., were ICC clients and no RDS participants had matching 
fingerprint data), identified by the RDS only (i.e., were sampled into the RDS with no fingerprint 
match to an ICC client), or identified by both the ICC and RDS (i.e., were RDS participants and 
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had matching fingerprints to an ICC client). Exploratory data analysis included the 
frequency/percentage and median/interquartile range (IQR) of characteristics by identification 
approach and chi-squared or Kruskal-Wallis tests were used for statistical comparison across 
categories and continuous characteristics, respectively. Correlates of identification by approach 
were explored using multinomial logistic regression with the ICC only group as the reference 
condition. Thus, odds ratios (ORs) for identification by RDS only and both ICC and RDS are 
compared to PWID that were ICC clients only.  
 
The main characteristic of interest was undiagnosed HIV infection defined as PWID who tested 
positive either at the ICC or RDS but did not report a prior diagnosis. For exploratory data 
analysis, individuals were also further categorized as HIV negative, HIV-infected and previously 
diagnosed, and having an unknown status. ICC clients could voluntarily request HCT services at 
the ICC at any time. A number of clients, especially those that visited the ICC infrequently, did 
not undergo HCT and did not have a record of HIV-specific care (i.e., CD4 count, ART 
registration number or refill information); therefore, their HIV status was classified as unknown. 
Clients who did not have a positive HIV test result at the ICC but reported a prior HIV diagnosis 
to the counselor or had a record of HIV care at the ICC were considered to be previously 
diagnosed. RDS study participants who had a positive test at the study visit and reported a prior 
diagnosis were considered to be previously diagnosed. HIV negative PWID were those with an 
HIV negative test either at the ICC or the RDS study visit. Since all RDS participants underwent 
HIV counseling and testing regardless of self-reported status and completed a questionnaire as 
part of the study procedures, all RDS participants had complete data on current HIV infection 
and diagnosis status, with the exception of three that had a missing infection status. Other 
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correlates investigated included basic socio-demographics (i.e., city, age, gender, marital status, 
and educational attainment), which were available for both ICC clients and RDS participants. 
 
To summarize the efficiency of ICCs and RDS in identifying undiagnosed HIV-infected PWID, 
we used two different measures: (1) the number needed to recruit (NNR) which is the number 
needed to recruit/screen in order to find one undiagnosed individual (total number of ICC clients 
or RDS participants / number of undiagnosed PWID identified) and (2) the identification rate 
which is the number of undiagnosed individuals identified per week (number of undiagnosed 
PWID identified / number of weeks ICC provided services or RDS recruitment was active). The 
lower the NNR, the more efficient an approach and the higher the rate, the more efficient an 
approach. The NNR and identification rate were calculated independently for the ICC client data 
set and RDS data set, for each city individually and pooled with all six cities. Calculation of the 
NNR and identification rate for the RDS excluded seeds and the first two waves of recruitment 
(n=71) to be consistent with the confidence interval calculation described below.  
 
Confidence intervals around the NNR were calculated using a bootstrap method for both the ICC 
and RDS data. For the ICC, 1000 samples with replacement of the ICC client data were taken 
and the NNR calculated for each sample. The 2.5th and 97.5th percentiles of the 1000 NNR 
estimates represent the 95% confidence interval. For the RDS, a sample with replacement of only 
the third wave of recruitment was conducted. For each individual sampled in wave 3, all their 
descendants (i.e., all recruits below them in the recruitment tree) were selected; the NNR was 
calculated. This process was repeated 1000 times and the 2.5th and 97.5th percentiles of the 1000 
NNR estimates represent the 95% confidence interval for the RDS NNR. Confidence intervals 
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for the ICC identification rate were exact Poisson confidence intervals. For the RDS, 95% 
confidence intervals around the identification rate were calculated in the same manner as the 
NNR with 1000 bootstrapped samples from wave 3 individuals with their descendants. The 
NNR/identification rate difference between the ICC and RDS was calculated by subtracting the 
RDS point estimate from the ICC point estimate; 95% confidence intervals around the difference 
were calculated using a bootstrap method similar to the confidence interval method described 
above for the NNR and rate using 1000 bootstrapped samples. 
 
Trends over time in the NNR and identification rate were examined using exploratory methods 
for the ICC and RDS data separately, for each city individually and all six cities pooled. 
Specifically, the NNR and rate were calculated for each week the ICC provided services/RDS 
recruitment was active. The first HIV test date or first ICC visit for those that never received an 
HIV test in the ICC were used for the ICC graph; the study visit date was used for the RDS 
graph.  
 
As a sensitivity analysis for the NNR and identification rate among ICC clients, the sample was 
restricted to the first 1000 clients to match the sample size of RDS participants in each city. The 
NNR and identification rate were re-calculated for the ICC with this restricted sample. For RDS 
data, a sensitivity analysis was conducted in which HIV-infected PWID who self-reported not 
previously being aware of their infection but had a suppressed viral load (<150 copies/mL) were 
reclassified as previously diagnosed since they were likely on antiretroviral therapy (n=90); the 
NNR and identification were then re-calculated. Viral load was very rarely available for ICC 
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clients since monitoring is not the standard of care for patients and therefore re-classification of 
diagnosis status based on viral load was not possible for ICC clients.  
 
All analyses were conducted using Stata (StataCorp. 2017. Stata: Release 15. Statistical 
Software. College Station, TX: StataCorp LLC). P-values were considered statistically 
significant at <0.05.  
 
To visualize the geographic reach of the ICC and RDS approaches, we mapped the pin code 
(similar to a US zip code) of residence for ICC clients only, RDS participants only, and both ICC 
clients and RDS participants in one city, Ludhiana. Ludhiana is represented by a larger number 
of pin codes in comparison to the smaller northeast/central cities and had more valid/known pin 
codes in the data, thus allowing for better differentiation for mapping the two approaches. PWID 
with unknown or invalid pin codes were dropped from the mapping analysis. For each 
individual, the geodesic distance (i.e., as the crow flies) in kilometers (km) was calculated from 
their pin code of residence centroid to the ICC or RDS address using latitude and longitude for 
both points. For persons that were both ICC clients and RDS participants the longest distance 
(either to the ICC or RDS site) was used. Mean (standard deviation [SD]) distances from the 
residence centroid to the ICC/RDS site were compared with a one-way ANOVA to test for 
significant differences across the three categories of PWID. Outliers, distances greater than 
100km (n=7), were dropped from analyses. Distances were calculated and maps were created 
using ArcGIS version 10.2 (Redlands, CA, US) using OpenStreetMap as the base layer 





This study was approved by the institutional review boards of Johns Hopkins Medicine and the 
Y.R. Gaitonde Centre for AIDS Research and Education. 
 
RESULTS 
There was a total of 10,759 ICC clients and 6,012 RDS study participants. After evaluating 
overlap in the two approaches, nearly 40% of RDS participants were also ICC clients resulting in 
14,397 unique PWID; 8385 (58.2%) were ICC clients only, 3638 (25.3%) were RDS participants 
only, and 2374 (16.5%) were both ICC clients and RDS participants. Median age of the sample 
was 29 (interquartile range [IQR]: 24-36), 10.4% were women, 46.8% were currently married, 
and 82.9% completed at least secondary level education. Overall, 71.4% were HIV negative, 
5.2% were HIV-infected but undiagnosed, 12.6% were HIV-infected and previously diagnosed, 
and 10.8% had an unknown HIV status. 
 
Socio-demographics and HIV infection/diagnosis significantly differed across the three 
identification approaches (Table 2.1). ICC clients were more likely to be women (15.1% vs. 
3.4% and 4.8% for RDS only and both ICC and RDS, respectively). RDS participants were more 
likely to be widowed/divorced/separated (10.0% vs. 6.1% and 5.1% for ICC only and both ICC 
and RDS, respectively), to have completed a high school education or more (24.1% vs. 15.2% 
and 13.0%), and to be HIV-infected but undiagnosed (9.4% vs. 3.4% and 5.4%).  
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In multivariable analysis adjusted for socio-demographics and HIV infection/diagnosis status, 
these differences persisted (Table 2.2). Men were nearly 7 times more likely to be sampled by 
the RDS only (adjusted odds ratio [aOR]: 6.84, 95% confidence interval [CI]: 5.61 - 8.35) and 
nearly 3 times more likely to be both ICC clients and RDS participants (aOR: 2.72, 95% CI: 2.21 
- 3.35) compared to ICC clients only. Widowed/divorced/separated PWID had 2 times higher 
odds of being in the RDS only (aOR: 2.03, 95% CI: 1.71 - 2.40). PWID with at least a high 
school education had 1.75 times higher odds of being in the RDS only (aOR: 1.75, 95% CI: 1.54 
- 2.00). RDS participants and both ICC clients and RDS participants had 2.5 times and 1.5 times 
higher odds of being HIV-infected but undiagnosed, respectively, compared to ICC clients only 
(aOR: 2.46, 95% CI: 2.07 - 2.93 and aOR: 1.52, 95% CI: 1.22 - 1.90). 
 
Number needed to recruit (NNR) 
The overall NNR for the ICC was 26.1 (95% CI: 23.8 - 28.8) and for the RDS was 10.9 (9.2 - 
13.2), implying on average the ICC required screening 26 PWID in order to find one 
undiagnosed individual while the RDS required screening 11 to find one undiagnosed individual 
(Figure 2.1). Stratified by city, the ICC NNR ranged from 10.2 to 73.5 and the RDS NNR 
ranged from 4.5 to 27.4. The NNR for RDS was markedly lower than the ICC overall and in all 
cities, with the exception of Bilaspur. The difference between the ICC and RDS ranged from 7.2 
to 54.1 (excluding Bilaspur) additional individuals needed to be screened in the ICC for one 
additional undiagnosed PWID, with lowest lower bound of the 95% CI of 4.1 (Supplementary 
Table 2.1).  
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The NNR over time for the ICCs (pooling all six cities) did not indicate a specific temporal or 
seasonal pattern (Figure 2.2a), rather it appears somewhat stable with peaks appearing at 
random times. The ICC NNR also appears stable over time when stratified by city 
(Supplementary Figures 2). The NNR for the RDS (pooling all six cities) indicates a slow 
steady increase over weeks of recruitment (Figure 2.2b). However, when stratified by city, the 
patterns vary (Supplementary Figures 2); in some cities, there is a suggestion of an increase in 
the RDS NNR over time (Aizawl, Bilaspur, Imphal) while others appear to decrease over time 
(Chandigarh, Dimapur) or have no identifiable pattern (Ludhiana).  
 
Identification rate 
The overall identification rate per week for the ICC was 2.7/week (95% CI: 2.5 - 3.0) and for the 
RDS was 18.6/week (95% CI: 14.0 - 24.1) (Figure 2.3). By city, the ICC rate ranged from 0.2 to 
1.0 and the RDS rate ranged from 1.7 to 16.0. The identification rate was meaningfully higher 
for RDS than the ICC overall and in all cities. The rate difference between the ICC and RDS by 
city ranged from 1.5 to 15.1/week additional undiagnosed PWID identified by the RDS. 
(Supplementary Table 2.1). 
 
Similar to the NNR, the identification rate over time for the six pooled ICCs appears somewhat 
stable over time with peaks at random times (Figure 2.2c). For the Aizawl ICC, the rate appears 
higher in the later weeks while for Bilaspur, the rate appears higher in the earlier weeks; 
otherwise, the other ICC city-specific identification rates appear stable over time 
(Supplementary Figures 2).  The identification rate for the RDS indicates a sharp increase in 
the first several weeks then a slow steady decrease (Figure 2.2d). Aizawl, Bilaspur, and Imphal 
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RDS show a similar pattern (decreasing rate over time); however, the other city-specific rates are 
more erratic with no clear pattern (Supplementary Figures 2). 
 
NNR and identification rate sensitivity analyses 
When restricting to the first 1000 ICC clients, the overall ICC NNR decreased (26.1 to 23.1) 
(Supplementary Table 2.2) and in each city the NNR was slightly lower or similar, with the 
exception of Aizawl in which the NNR increased substantially (11.7 to 17.5). The NNR 
difference between the ICC and RDS generally decreased but remained meaningful with the 
exception of Bilaspur. The identification rate was lower when restricting to the first 1000 ICC 
clients, overall (2.7 to 1.7/week) and in each city. The rate difference between the ICC and RDS 
increased slightly and remained markedly different.  
 
After re-classifying undiagnosed RDS participants with undetectable viral loads, the RDS NNR 
increased, overall (10.9 to 13.1) (Supplementary Table 2.3) and in each city. The NNR 
difference between the ICC and RDS decreased slightly but remained meaningful, with the 
exception of Ludhiana (difference: 4.2, 95% CI: -4.3 to 10.7).  For the RDS NNR over time, the 
pattern remained the same - increasing over weeks of recruitment - after reclassification (Figure 
2.2b). The overall RDS identification rate decreased (18.6 to 15.5) and in each city the rate was 
lower or similar. The rate difference between the ICC and RDS decreased but remained large. 
For the identification rate over time, the pattern remained the same - a sharp increase in the first 
several weeks followed by a slow steady decrease - after reclassification (Figure 2.2d). 
 
Geographic reach of ICC and RDS 
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In Ludhiana, 9.3% of PWID did not know their pin code of residence or reported an invalid pin 
code. However, this was differential by group: 11.5% among ICC clients only, 0.3% among RDS 
participants only, and 16.9% among both ICC clients and RDS participants. Pin code maps of 
ICC clients and RDS participants in Ludhiana (Figure 2.4) indicate that PWID who were ICC 
clients only or both ICC clients and RDS participants generally lived closer to the city center 
(nearer to both the ICC and RDS site). In comparison, more PWID who were RDS study 
participants came from areas farther from the city center. The mean distance between an RDS 
participant’s pin code and the RDS site (11.2 km, SD: 10.8 km) was significantly higher 
(p<0.001) than the mean distance for ICC clients (7.5 km, SD: 4.6 km) and those that were both 
ICC clients and RDS participants (9.2 km, 4.4 km).  
 
DISCUSSION 
As compared to ICCs - a venue-based strategy - RDS required screening fewer PWID and more 
rapidly identified undiagnosed HIV-infected PWID. On average, RDS screened 15 fewer PWID 
in order to identify one undiagnosed PWID and identified nearly 16 more undiagnosed PWID 
each week compared to ICCs. These meaningful differences were seen in all six cities 
individually, with the exception of the NNR in Bilaspur. Additionally, population demographics 
varied across the strategies; men, those widowed/divorced/separated, and with higher education 
were more likely to be RDS participants than ICC clients. In one city where we were able to map 
area of residence, the data suggests that RDS reaches PWID that live farther from the RDS study 
site while ICC clients generally reside closer to the ICC in the central area of the city.  
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Other investigations of the ability of RDS to identify undiagnosed people living with HIV 
(PLWH) compared to other strategies have found similar results. A study by Gwadz and 
colleagues found that among high-risk heterosexuals in New York City, RDS yielded 
significantly more individuals with newly diagnosed HIV as compared to venue-time-based 
sampling from commercial areas21. Kan and colleagues compared RDS, both with and without 
restricting recruitment waves based on HIV status, to peer community outreach among PWID in 
several different areas in Tajikistan and found those recruited through RDS were more likely to 
be new positives than the outreach strategy22. However, not all studies have found an improved 
efficiency associated with RDS. Among people who used crack in San Salvador, Glasman and 
colleagues found a similar percentage of new HIV diagnoses among testers in a self-referral and 
peer-referral period, both lasting 14 months, though the absolute number of new diagnoses was 
nearly twice as high in the peer-referral time period23. Among African American MSM in 
Baltimore, a social network strategy very similar to RDS was used in which HIV-infected MSM 
recruited social network members24. Ellen and colleagues found that this network strategy as 
well as testing partners of HIV-infected persons found no new HIV positives while a venue-
based strategy identifying MSM from areas where they socialize and meet new sex partners 
yielded about 10% new diagnoses. Importantly, in this network strategy, only HIV-infected 
MSM were able to recruit others which is a key departure from the typical way in which RDS is 
conducted. Therefore, the effectiveness of RDS to identify undiagnosed PLWH may differ across 
populations and contexts when compared to other common strategies that are employed such as 
community outreach, partner testing, or venue/clinic-based strategies. 
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While RDS was overall more efficient in identifying undiagnosed HIV-infected PWID than the 
ICCs, an ideal scenario would employ both approaches to ensure that progress is made along the 
entire HIV continuum, not just the first step, and addresses prevention needs. PWID that are HIV 
negative require continued engagement with counseling, support, and access to harm reduction 
and other HIV prevention services to remain uninfected. Additionally, HIV-infected PWID once 
diagnosed need immediate linkage to care and treatment with potentially many decades of 
medical care and ART support. While RDS can quickly identify undiagnosed PLWH, ICCs or 
similar venue- or clinic-based settings provide other vital services. Importantly, for populations 
such as PWID that often experience stigma and discrimination while accessing services, settings 
like ICCs offer a safe space specifically tailored for them. Additionally, ICCs were more likely 
to identify women who inject drugs compared to the RDS, possibly due to different network 
characteristics than men. Women are a particularly vulnerable sub-group of PWID in India7,25,26 
and any interventions or approaches that successfully engage them in HIV-related prevention and 
care should be promoted.  
 
There are several limitations to this work that should be noted. For the main analysis, awareness 
of HIV-positive status was self-reported in the RDS and ICC data which is subject to recall or 
reporting bias. A sensitivity analysis in which RDS participants with suppressed viral load but 
did not report a prior diagnosis were reclassified as previously diagnosed did not change the 
overall inference that RDS was more efficient than the ICCs. However, since viral load was not 
routinely collected from ICC clients, this sensitivity analysis is restricted to only RDS 
participants. The two approaches explored - the RDS and ICCs - did not run completely 
concurrently. The RDS period fully overlapped with the provision of services by ICCs in each 
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city but ICCs began approximately two years before the evaluation RDS was initiated. Temporal 
changes and population migration could have occurred changing risk behaviors and/or 
population characteristics. Lastly, inherent to most RDS studies, monetary compensation is 
provided to study participants for completing study procedures and successfully recruiting other 
eligible study participants into the study; use of ICC services was not compensated. We are 
unable to separate out the effect of a network-driven strategy and compensation within the RDS 
on its efficiency and how that may affect its efficiency in relation to the ICCs. 
 
In summary, the ability of RDS to more efficiently identify undiagnosed HIV-infected PWID 
compared to ICCs in India suggests that similar network-driven strategies with minimal 
compensation could be used to identify and engage groups not currently visiting venues or 
clinics for HIV prevention and care services. Given the very fast approaching deadline for the 
UNAIDS 90-90-90 target, finding and implementing effective and efficient methods to improve 
HIV diagnosis, treatment initiation, and viral suppression for all populations affected by HIV, 
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Table 2.1 Socio-demographic characteristics and HIV status by identification approach among 
PWID in India 
Characteristic 








































































Primary or less 
Secondary school 





























PWID: people who inject drugs; IQR: interquartile range; ICC: integrated care clinic; RDS: respondent-driven sampling 
1: Chi-square test for categorical characteristics and Kruskal-Wallis test for continuous characteristics 
 47 
Table 2.2 Correlates of identification by RDS only and both ICC and RDS as compared to ICC only among PWID in India 






















0.85 - 1.09 
0.24 - 0.32 
1.24 - 1.67 
0.74 - 0.98 







0.45 - 0.68 
0.83 - 1.15 
3.56 - 5.09 
2.15 - 3.03 







1.15 - 1.53 
0.23 - 0.31 
1.23 - 1.70 
0.78 - 1.06 







0.52 - 0.81 
0.79 - 1.11 
3.38 - 4.92 
2.08 - 2.98 
1.12 - 1.61 
Age, by 10-year increase 0.87 0.85 - 0.93 0.95 0.90 - 1.00 0.96 0.90 - 1.02 1.07 1.01 - 1.15 
Men (vs. women)2 5.07 4.19 - 6.13 3.55 2.91 - 4.32 6.84 5.61 - 8.35 2.72 2.21 - 3.35 
Marital status 
Married/long-term 






1.12 - 1.32 




1.06 - 1.28 




0.90 - 1.09 




0.95 - 1.18 
0.95 - 1.18 
Educational attainment 
Primary or less 
Secondary school 




0.53 - 0.64 




0.81 - 1.03 




0.62 - 0.77 




0.89 - 1.14 











1.85 - 2.56 







1.23 - 1.89 
1.11 - 1.42 
0.30 - 0.42 
-- -- -- -- 
Undiagnosed HIV positive 2.96 2.52 - 3.48 1.65 1.33 - 2.04 2.46 2.07 - 2.93 1.52 1.22 - 1.90 
RDS: respondent-driven sampling; ICC: integrated care clinic; PWID: people who inject drugs; OR: Odds ratio from multinomial logistic regression, reference outcome is identification by ICC only; CI: 
confidence interval;  









Supplementary Table 2.1 Number needed to recruit (NNR) and identification rate difference 





Rate difference1 95% CI 
Overall 15.2 12.0 - 18.4 -15.9 -21.5, -11.4 
Aizawl 7.2 5.4 - 9.7 -15.1 -25.9, -6.43 
Dimapur 45.4 24.8 - 87.5 -2.2 -3.9, -1.0 
Imphal 54.1 35.6 - 81.7 -2.5 -5.0, -0.6 
Bilaspur 1.2 -1.3 - 3.7 -4.0 -5.2, -2.9 
Chandigarh 34.6 14.6 - 72.2 -1.5 -2.4, -0.7 
Ludhiana 8.9 4.1 - 14.0 -2.3 -3.5, -1.2 
1: RDS estimate subtracted from ICC estimate  
ICC: Integrated care clinics; RDS: respondent-driven sampling 
NNR: Average number of people who inject drugs (PWID) recruited/screened in order to identify one undiagnosed 
HIV-infected PWID 
Identification rate per week: Average number of undiagnosed PWIED identified per week 
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Supplementary Table 2.2 Number needed to recruit (NNR) and identification rate per week for 
undiagnosed HIV-infected PWID restricted to the first 1000 ICC clients, overall and by city 
 
 NNR 95% CI Identification Rate 95% CI 
Overall 23.1 20.6 - 26.2 1.7 1.5 - 1.9 
Aizawl 17.5 14.1 - 23.3 0.4 0.3 - 0.6 
Dimapur 55.6 37.0 - 90.9 0.1 0.1- 0.2 
Imphal 71.4 45.5 - 142.9 0.1 0.05 - 0.2 
Bilaspur 9.9 8.3 - 12.1 0.8 0.6 - 0.9 
Chandigarh 45.5 32.3 - 76.9 0.2 0.1 - 0.3 
Ludhiana 20.8 16.4 - 27.8 0.3 0.3 - 0.5 
ICC: Integrated care clinics 
NNR: Average number of people who inject drugs (PWID) recruited/screened in order to identify one undiagnosed 
HIV-infected PWID 
Identification rate per week: Average number of undiagnosed PWIED identified per week 
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Supplementary Table 2.3 Number needed to recruit (NNR) and identification rate per week for 
undiagnosed HIV-infected PWID in the RDS after re-classification of self-reported undiagnosed 
HIV-infected PWID with undetectable viral loads 
 
 NNR 95% CI Identification Rate 95% CI 
Overall 13.1 11.1 - 15.6 15.5 11.6 - 20.6 
Aizawl 5.3 4.3 - 5.9 13.5 6.4 - 22.2 
Dimapur 26.0 17.3 - 31.5 2.1 1.2 - 3.4 
Imphal 28.2 21.2 - 41.2 1.9 0.7 - 3.5 
Bilaspur 9.8 8.3 - 11.8 4.5 3.5 - 5.5 
Chandigarh 28.2 23.5 - 39.4 1.6 0.8 - 2.6 
Ludhiana 16.7 13.0 - 24.8 2.0 1.0 - 3.1 
RDS: respondent-driven sampling 
NNR: Average number of people who inject drugs (PWID) recruited/screened in order to identify one undiagnosed 
HIV-infected PWID 
Identification rate per week: Average number of undiagnosed PWIED identified per week 
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Background Novel strategies are needed to reach the UNAIDS 90-90-90 target, especially for 
PWID and other key populations. Respondent-driven sampling (RDS) is a rapid, effective 
method for reaching PWID. The objective of this analysis was to explore easy-to-collect 
characteristics of PWID associated with recruiting undiagnosed or viremic people who inject 
drugs living with HIV (PLWH) into an RDS sample and identify in which settings these 
characteristics predict recruitment best. 
 
Methods In 2013, a cross-sectional sample of 14,481 PWID across 15 Indian cities (~1000/city) 
was accrued using RDS, initiated by two seeds; all participants were given 2 coupons to recruit 
other PWID. Participants underwent a blood draw, HIV testing, and completed a survey. 
Undiagnosed PLWH were individuals who tested positive and denied a prior diagnosis; viremic 
PLWH were individuals with a detectable HIV viral load. We evaluated predictive accuracy of 
recruiter characteristics in recruitment of undiagnosed/viremic PLWH using the area under the 
receiver operator curve (AUROC) from logistic regression models and a final multivariable 
model was applied to bootstrapped samples of each city to examine predictive ability in different 
types of settings. 
 
Results Median age was 30, most were men (94%), and 20% were HIV-infected, of whom 58% 
were previously undiagnosed; 10% and 13% of participants recruited an undiagnosed and 
viremic PLWH, respectively. HIV and HCV infection along with factors associated with higher 
HIV risk (e.g., sharing needles/syringes, large network size) were most strongly associated with 
recruiting an undiagnosed/viremic PLWH. Among PWID with HIV/HCV co-infection, a large 
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network size (≥51), and that reported sharing needles/syringes in the prior 6 months, 25% 
recruited at least one undiagnosed PLWH and 34% recruited a viremic PLWH. A multivariable 
model with 10 characteristics predicted with moderate ability the recruitment of an undiagnosed 
(AUROC=0.67) and viremic (0.66) PLWH. The model performed best in areas with low harm 
reduction access and for recruitment of an undiagnosed PLWH, prediction was best in settings 
with low HIV/HCV services and high HIV incidence. 
 
Conclusions Recruitment patterns suggest PWID with HIV/HCV infection, who are central in 
their network, and engage in risky behaviors are more likely to recruit PWID with 
undiagnosed/viremic HIV. These easily obtainable characteristics could be used to target an RDS 





In 2014, UNAIDS set an ambitious target to end the HIV epidemic by 2020, which we are 
rapidly approaching. The target aims for 90% of all those living with HIV to be diagnosed, 90% 
of those diagnosed to be on sustained antiretroviral therapy (ART), and 90% of those on ART to 
have undetectable viral load1. Importantly, these must be approached with principles of human 
rights and inclusion of all those living with HIV, especially key populations (e.g., men who have 
sex with men [MSM], people who inject drugs [PWID], transgender individuals, sex workers) 
who experience stigma, discrimination, and marginalization, continue to have a disproportionate 
burden of HIV2, and often lag behind the general population in the HIV care continuum and 90-
90-90-target3. In many areas of the world, HIV epidemics are growing due to injection drug use; 
PWID account for an estimated 30% of new infections outside sub-Saharan Africa4. 
 
Respondent-driven sampling (RDS), a type of chain referral sampling, is now widely used in 
HIV research and surveillance, especially in key populations such as MSM, PWID, and female 
sex workers5,6. These populations do not have known sampling frames from which to sample and 
can be more difficult to reach due to stigma and criminalization. RDS is able to overcome these 
barriers by leveraging individuals’ social networks for direct recruitment of study participants 
from the target population itself, rather than being driven by study staff. Given a set of 
assumptions, estimates can be weighted to produce unbiased population characteristics of the 
underlying target population7, such as HIV prevalence or risk behaviors, which is most often the 
goal of the research - to characterize the epidemic and risk factors in a particular population to 
guide public health funding and programs.  
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Among PWID from 15 cities across India in 2013, we previously found that the largest drop in 
the HIV care continuum was at diagnosis with only approximately 40% of those HIV-infected 
being aware of their status8 - well below the UNAIDS target of 90%. Quickly identifying persons 
living with HIV who are undiagnosed or not on ART is vital, not only for their individual health 
and well-being, but because they are likely to have high viral loads and thus able to efficiently 
transmit HIV to others such as their sexual or injecting partners. In our prior work, we found 
RDS to be a rapid, effective method for reaching PWID and MSM in India, especially those who 
are HIV-infected but undiagnosed or viremic9. Other researchers have similarly observed that 
among MSM in sub-Saharan Africa, HIV-infected study participants recruited in later waves of 
an RDS (i.e., deeper in the network) were less likely to be aware of their status10,11. Therefore, 
not only is RDS an efficient way to reach these key populations in general but RDS may 
specifically help to identify individuals within these populations that may be even more difficult 
to reach, less likely to self-refer to services, and/or be unaware of their HIV risk. These data 
collectively support the use of RDS as a strategy to reach people at high-risk for HIV and that are 
not currently engaging in HIV-related services. Such strategies are especially important given the 
UNAIDS 90-90-90 target. 
 
Since RDS rapidly reached a large number of PWID, especially those that were not engaged in 
HIV-related services, it is of interest to understand whether it might be possible to steer RDS to 
increase the efficiency of identifying undiagnosed or viremic PWID living with HIV (PLWH). 
The objective of this analysis was to explore easy-to-collect characteristics of PWID associated 
with recruiting undiagnosed or viremic PLWH into an RDS sample and to identify in which 





Data used for this analysis were collected as part of a cluster-randomized trial, the National 
Collaboration on AIDS (NCA) trial (ClinicalTrials.gov identifier: NCT01686750) among MSM 
and PWID in India12. This analysis is restricted to the cross-sectional baseline assessment data of 
the PWID stratum. 
 
Participants were recruited using RDS from 15 different Indian cities (Table 3.1), representing 
different regions and stages of the HIV epidemic (i.e., both established epidemics and emerging 
epidemics), between January and December 2013. Approximately 1000 PWID were recruited in 
each city, with the exception of Moreh, where recruitment was stopped early due to civil unrest 
in the area. The RDS was initiated in each city using 2 seeds (3 in Gangtok); seeds are PWID 
that are well-connected and influential in their community. Each seed and subsequent study 
participant were given two recruitment coupons to distribute to others that they know inject 
drugs in the city. Coupons were bar-coded with identification numbers to link recruiters and their 
recruits and included a hologram to prevent duplication of coupons. Individuals that received a 
coupon, voluntarily visited the study center, and if eligible, were enrolled, completed study 
procedures, and received 2 recruitment coupons to distribute to their network at random. 
Recruitment continued until the desired sample size in each city was met (1000). Eligibility 
criteria to enroll in the study included (1) being at least 18 years old, (2) provision of informed 
consent, (3) possession of a valid coupon unless a seed, and (4) self-reported injection drug use 
in the prior 24 months. Dual incentives were provided for study participation and recruitment. 
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Study participants received INR 250 (US $3.8) for completing study procedures and INR 50 (US 
$0.80) for each eligible study participant they recruited into the study. 
 
Study procedures 
Following consent, study participants provided a blood sample and completed an interviewer-
administered questionnaire that collected information on socio-demographics, HIV and HCV 
testing and care history, injection and sexual risk behaviors, harm reduction, and network 
characteristics. HIV pre- and post-test counseling in addition to appropriate referrals to care for 
HIV-infected participants were provided with rapid HIV testing. HIV testing was conducted in 
accordance with Indian guidelines using 3 rapid tests: Alere Deterimine 1/2 (Alere Medical, 
Chiba, Japan), First Response HIV Card Test 1-2.0 (Premier Medical Corporation, Daman, 
India), and Signal Flow Through HIV 1+2 Spot/Immunodot Test Kit (Span Diagnostics, Surat, 
India). Using stored blood samples, HCV antibody testing was conducted using Genedia HCV 
ELISA 3.0 (Green Cross Medical Science, Chungbuk, Korea) and HIV-1 RNA (viral load) 
quantification was conducted for all HIV-infected participants using Abbott RealTime HCV 
assay (Abbott Laboratories, Abbott Park, Illinois, US). 
 
Statistical methods 
The main outcome of interest is recruitment of at least one undiagnosed PWID living with HIV 
(PLWH) via the RDS. A participant was defined as undiagnosed if they had a positive HIV test 
at the study visit and denied a prior diagnosis on the questionnaire. Identification codes on the 
recruitment coupons allowed for the linkage of recruiter and their recruits in the data. If a study 
participant recruited no one or only HIV negative study participants or PLWH that were 
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diagnosed prior to the study, they were considered not to have the outcome of interest. There 
were a number of participants (n=251) who were HIV-infected and did not report a prior 
diagnosis but had an undetectable viral load (<150 copies/mL). These participants were 
categorized as previously diagnosed, since they were likely on antiretroviral therapy (confirmed 
via a sub-study on ART levels in blood samples). As a secondary analysis, we examined an 
objective outcome, namely recruitment of at least one viremic (HIV viral load ≥150 copies/mL) 
PLWH, regardless of self-reported diagnosis status. 
 
Exploratory data analysis included the frequency/percentage and median/interquartile range 
(IQR) of characteristics by outcome status - recruiting/not recruiting an undiagnosed/viremic 
PLWH. The percentages and medians/IQRs are unweighted as the focus of this analysis is the 
pattern of RDS recruitment, not any inference to the underlying target population. Correlates of 
recruiting an undiagnosed/viremic PLWH were explored using logistic regression models. 
Correlates selected for investigation were easy-to-collect and broadly characterize the PWID 
population and their HIV risk; they include self-reported socio-demographics (age, gender, 
marital status, education), injection risk behaviors (injection duration and sharing 
needles/syringes), harm reduction services utilization (needle/syringe exchange program [NEP] 
and opioid agonist therapy [OAT]), PWID network size (categorized using quartiles) and HIV 
and HCV status. Logistic regression models used a complete case analysis, dropping any 
observation with a missing correlate. Missingness was minimal with no more than 0.4% missing 
for any correlate: gender and marital status (n=1), HIV status (n=1), HCV status (n=2), and 
injection duration (n=57). The predictive accuracy of each correlate was assessed using the area 
under the receiver operator curve (AUROC) from the logistic regression. 
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Multivariable logistic models using all 15 cities were constructed including different 
combinations of characteristics. The overall predictive accuracy of the models was assessed 
using the AUROC. AUROCs of each model were statistically compared to identify the most 
parsimonious and predictive multivariable model (i.e., the final multivariable model). 
Additionally, for combinations of specific characteristics (e.g., HIV/HCV co-infected and with a 
large network size), recruitment efficiency was calculated which is the percent of individuals 
with the specific characteristic combination that recruited an undiagnosed/viremic PLWH.  
 
To examine in which type of setting the final multivariable model best predicts recruiting an 
undiagnosed/viremic PLWH, we applied the multivariable model coefficients to 1000 
bootstrapped samples of each city. First, separately for each city, participants were sampled with 
replacement from the third wave of recruitment. For any wave three participant that was 
sampled, all their descendants were included. Coefficients from the multivariable model were 
applied to this bootstrapped sample and the AUROC calculated. This process was repeated 1000 
times for each city. The median and 2.5% and 97.5% percentile of the 1000 AUROCs were the 
AUROC point estimate and 95% confidence interval, respectively, for that city. In one or more 
of the bootstrapped samples for Gangtok and Moreh, no individuals had the outcome of interest 
(due to a low prevalence of the outcome in Gangtok and a high level of clustering of the outcome 
by recruitment chain in Moreh) and thus the AUROC could not be calculated for these two sites. 
Next, we calculated city-level characteristics including socio-demographics, HIV/HCV 
prevalence, annual HIV incidence, HIV care continuum outcomes, prevalence of HIV viremia 
(percent of total population with HIV viral load ≥150 copies/mL), HCV testing and awareness, 
 79 
harm reduction services utilization, and injection drug use risk behaviors. City-level 
characteristics were calculated incorporating RDS-II weights13 so that the characteristics are 
reflective of the underlying target population, with the exception of cross-sectional annual HIV 
incidence, which is unweighted and calculated using a validated multi-assay algorithm14. A 
Spearman rank correlation (ρ) was used to assess the relationship between the AUROC 
calculated from each of the city bootstrapped models and city-level characteristics. For moderate 
to strong correlations (ρ ≥ |0.3|), we further examined the relationship using a scatterplot of the 
AUROC and city-level characteristic with a linear prediction.  
 
Analyses were conducted using Stata (StataCorp. 2017. Stata: Release 15. Statistical Software. 
College Station, TX: StataCorp LLC). P-values were considered statistically significant at <0.05.  
 
Ethical clearances 
This study was approved by the institutional review boards of the Johns Hopkins University 
School of Medicine and the Y.R. Gaitonde Centre for AIDS Research and Education. 
 
RESULTS 
A total of 14,481 PWID were enrolled of whom 2,915 were HIV-infected (20%); 58% of PLWH 
were unaware of their infection. Median age was 30 years (IQR: 24 - 36), 6% were women, and 
90% were actively injecting drugs in the prior six months. Overall, 43% of participants did not 




Recruiting undiagnosed PLWH 
Approximately 9% (n=1286) of study participants recruited at least one undiagnosed PLWH. In 
univariable analysis, those that recruited an undiagnosed PLWH were significantly older (odds 
ratio [OR] per 10 year increase: 1.13, confidence interval [CI]: 1.06 - 1.21), more likely to be 
HIV and/or HCV-infected (HIV mono-infected OR: 1.69, 95% CI: 1.30 - 2.20; HCV mono-
infected OR: 2.36, 95% CI: 2.05 - 2.71; HIV/HCV co-infected OR: 3.60, 95% CI: 3.10- 4.18, all 
vs. HIV/HCV negative,), report recently sharing a needle/syringe (OR: 1.40, 95% CI: 1.24 - 
1.57), recently use a NEP (OR: 1.30, 95% CI: 1.16 - 1.46), and have a large PWID network (OR 
≥51 vs. ≤8: 1.74, 95% CI: 1.46 - 2.07) (Table 3.1). Women (OR vs. men: 0.67, 95% CI: 0.50 - 
0.89), those married or living with their partner (OR vs. never married: 0.86, 95% CI: 0.76 - 
0.97), and those with a higher education (OR at least high school vs. no/primary school: 0.62, 
0.52 -0.73) were less likely to recruit an undiagnosed PLWH. The independent predictive 
accuracy of the characteristics was lowest for recently using OAT (AUROC=0.50), injection 
duration (0.51), and gender (0.51). Predictive accuracy was highest for HIV/HCV status 
(AUROC=0.64) and city (0.71). 
 
The predictive ability of different multivariable models for recruiting an undiagnosed PLWH are 
presented in Table 3.2. Model 5 with demographics, HIV/HCV infection status, network size, 
injection duration, needle/syringe sharing, and harm reduction had the highest AUROC (0.67; 
95% CI: 0.65 - 0.68) and was significantly higher than all other models. However, the predictive 
ability of the model with only HIV/HCV infection status and network size was also fairly high 
(AUROC=0.64); addition of recently sharing a needle/syringe to this model did not significantly 
improve prediction. Compared to univariable analysis, associations tended to be similar in the 
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final multivariable analysis using model 5 (Table 3.1); recent NEP use was no longer 
significantly associated (OR: 1.09, 95% CI: 0.97 - 1.24) and injection duration became 
significantly negatively associated (OR by 5-year increase: 0.86, 95% CI: 0.82 - 0.91) after 
adjustment. Recruitment efficiency (Table 3.2) was highest among those with HIV/HCV co-
infection, a network size ≥51, and that recently shared a needle/syringe (24.7%). Second highest 
efficiency was among those with HIV/HCV co-infection and a network size ≥51 (18.8%).  
 
The AUROCs for each city using the bootstrap approach are presented in Table 3.3 along with 
city-level characteristics; AUROCs ranged from 0.66 to 0.50. Predictive ability was poorest in 
Bhubaneshwar (AUROC=0.50) and Aizawl (0.52). The Spearman rank correlation of the 
AUROC for each city and its city-level characteristics are presented in Figure 3.1. Using a cut-
off of |0.3| to indicate a moderate to strong correlation (shaded area of Figure 3.1), annual HIV 
incidence (ρ=0.54) was positively correlated with predictive ability. The percentage of PLWH 
satisfying steps in the HIV care continuum was negatively correlated with predictive ability, 
specifically, percentage aware of HIV positive status (ρ=-0.45), linked to HIV care (-0.48), 
antiretroviral therapy (ART) use among those eligible for treatment (-0.41), and undetectable 
HIV viral load among those ART eligible (-0.40). Percentage ever receiving an HCV test (ρ=-
0.35), aware of HCV positive status (-0.32), recently using a NEP (ρ=-0.79), and recently using 
OAT (-0.51) were also negatively correlated with predictive ability. NEP use was the only 
correlation that was statistically significant. Scatterplots with linear predictions for these city-




Recruiting a viremic PLWH 
Recruiting at least one viremic PLWH was marginally more common (n=1822, 12.6%) than 
recruiting an undiagnosed PLWH. Univariable associations and their AUROCs were comparable 
to recruiting an undiagnosed PLWH (Supplementary Table 3.1). Predictive ability of 
multivariable models for recruiting a viremic PLWH (Table 3.2) were also very similar to 
models recruiting an undiagnosed PLWH. Model 5 with demographics, HIV/HCV infection 
status, network size, injection duration, needle/syringe sharing, and harm reduction had the 
highest AUROC (0.66; 95% CI: 0.65 - 0.67) and was significantly higher than all other models; 
multivariable associations of characteristics were also similar to recruiting an undiagnosed 
PLWH (Supplementary Table 3.1). Efficiency also showed the same pattern; recruitment 
efficiency was highest among those with HIV/HCV co-infection, a network size ≥51, and who 
recently shared a needle/syringe (33.8%). Second highest efficiency was among those with 
HIV/HCV co-infection and a network size ≥51 (28.1%). 
 
The AUROCs for each city using the bootstrap approach were slightly higher compared to 
recruiting an undiagnosed PLWH and the relative ability of the model to predict in each city 
differed from what was observed for undiagnosed PLWH (Table 3.1). AUROCs ranged from 
0.77 to 0.55. Predictive ability was positively correlated with the percentage with at least a 
secondary school education (ρ=0.45) and the percentage female (0.42) (Figure 3.1). Similar to 
recruiting an undiagnosed PLWH, the percentage recently using a NEP (ρ=-0.43) and OAT (-
0.38) were negatively correlated with predictive ability, though to a lesser extent. Scatterplots 
with linear predictions for these city-level characteristics and bootstrapped AUROCs are 
presented in Figure 3.2b.  No HIV- or HCV-related city-level characteristics were moderately or 
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strongly correlated with predictive ability of recruiting a viremic PLWH and no correlations 
reached statistical significance.  
 
DISCUSSION 
Using easy-to-collect characteristics of PWID, we were able to predict which individuals are 
most likely to know and recruit an undiagnosed and viremic PLWH into an RDS. HIV and HCV 
infection along with factors associated with higher HIV risk were most strongly associated with 
recruiting an undiagnosed and viremic PLWH. Among PWID with HIV/HCV co-infection, a 
large network size, and that recently shared needles/syringes, a quarter recruited an undiagnosed 
PLWH and a third recruited a viremic PLWH. Together, a multivariable model with 10 
characteristics including basic demographics, HIV/HCV status, injection drug use 
characteristics/behaviors, harm reduction service utilization, and network size was able to predict 
with moderate ability the recruitment of an undiagnosed and viremic PLWH. When this model 
was applied to different contexts across India, it performed best in areas with low harm reduction 
access. Additionally, specifically for recruitment of an undiagnosed PLWH, prediction was best 
in settings with low HIV/HCV services availability or accessibility in addition to areas with 
emerging or ongoing epidemics (i.e., high HIV incidence).  
 
Similar to our findings, prior studies examining RDS recruitment patterns among PWID in 
Mexico and the United States found that HIV-infected RDS participants are more likely to 
recruit others that are HIV-infected15,16. Our findings go one step further to suggest that those 
HIV-infected - whether they are aware of their status or not - are more likely to know and recruit 
someone that is HIV-infected but undiagnosed or viremic. This assortativity or homophily 
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(similarity or preference for others with similar characteristics) within RDS recruitment chains 
by HIV status was expected as HIV infection tends to cluster within social or injecting networks, 
a result of direct transmission and/or similar high-risk behaviors (e.g., frequency of injecting, 
sharing of injection paraphernalia)17,18. We also found that prevalent HCV infection was 
associated with recruiting an undiagnosed and viremic PLWH, with those co-infected with HCV 
and HIV most strongly associated. It is possible that co-infected PWID are currently or were 
frequently engaging in high-risk behaviors and are therefore more likely to be socially connected 
to others with similar behaviors. Though one of the assumptions of RDS recruitment is random 
selection of individuals within a person’s network13, it is also possible that people are 
preferentially recruiting individuals based on certain characteristics as others have found19-22. 
Without data on the full sociometric network or in-depth questions on network characteristics, it 
is difficult to ascertain which scenario is the truth23 - are HIV-infected PWID more likely to 
know someone that is HIV-infected but undiagnosed or are they choosing to recruit a network 
member that is engaging in more high-risk behaviors? The answer to this has implications for 
calculating population estimates using RDS data24 but if using RDS as a strategy to identify 
individuals in order to engage them in HIV services, there need not be a distinction. 
 
Our multivariable prediction model for recruiting an undiagnosed and viremic PLWH included 
only 10 covariates that would take 5 minutes or less to collect from PWID, with the exception of 
rapid tests for HIV and HCV, which would likely take about 20-30 minutes. Together, these 
characteristics were able to predict with fairly high ability given the rare outcomes - only 9% and 
13% of the sample recruited an undiagnosed or viremic PLWH, respectively. However, results 
suggest that the predictive ability of the model varied by setting. For recruitment of both 
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undiagnosed and viremic PLWH, better predictive ability was seen in cities with lower 
utilization of NEP and OAT. For undiagnosed PLWH, the model also performed better in areas 
with high HIV incidence and in those that were doing worse in terms of the HIV care continuum, 
specifically low levels of diagnosis, linkage to care, antiretroviral therapy use, and undetectable 
viral load among positives. Similarly, predictive ability was better in cities where fewer PWID 
had ever been tested for HCV and fewer of HCV-infected PWID were aware of their status. This 
is somewhat intuitive since undiagnosed PLWH would be more prevalent and well-connected 
within PWID networks in settings in which there are higher numbers of new HIV infections but 
little access to basic harm reduction and HIV/HCV services compared to those in settings with 
successful harm reduction and HIV service programs for PWID. Therefore, our findings suggest 
that using a network-based approach similar to RDS in which recruitment is steered using these 
basic predictors in order to identify more undiagnosed PLWH would be most appropriate and 
effective for settings with growing HIV epidemics and low PWID-targeted and HIV service 
availability. Available information or data on a local epidemic could be used to determine the 
appropriateness of this approach or alternatively, an RDS could be run for at least six waves - 
when equilibrium of characteristics is generally reached25 - to characterize the HIV epidemic, 
PWID harm reduction, and HIV/HCV service utilization. 
 
Predictors were very similar for the two outcomes, recruitment of an undiagnosed PLWH and a 
viremic PLWH. Given the very low awareness of HIV-infected PWID, a large portion of the 
viremic population - more than two-thirds - are indeed undiagnosed, which may explain this 
finding. On the other hand, the settings in which the multivariable model performed best differed 
for the two. There is significant variability across the different Indian regions and cities 
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represented in our sample, especially in the availability and accessibility of HIV-related services 
and therefore HIV care continuum outcomes among PWID8. This results in different mixtures of 
undiagnosed individuals and viremic individuals within the population of people living with 
HIV, making the application of one model for recruiting a viremic PLWH across different 
contexts less helpful. However, the ultimate goal of any HIV program or intervention is to 
reduce the number of viremic individuals in the population in order to reduce transmission, as 
evidenced by the UNAIDS 90-90-90 target, treatment as prevention (TasP), and the recent U=U 
campaign26. Diagnosis is only the first step; there must also be continued strong support for 
people living with HIV through all stages of care including access and adherence to effective 
therapy. 
 
There are several limitations to this work. Awareness of HIV status, as well as most of the 
predictors, were self-reported using the interviewer-administered questionnaire which is subject 
to biases such as recall and social desirability bias. Trained interviewers were used to mitigate 
these biases. To partially address this issue for our main outcome, we were able to identify and 
re-classify HIV-infected individuals that did not report a prior diagnosis but were likely to 
already be aware of their status because of an undetectable viral load. While the sample size for 
the individual-level analyses was quite large (>14,000), the correlation analysis to explore in 
which settings our prediction model performed best was at the city-level thus only had a sample 
size of 13 and 14. This limited our statistical power to identify which city-level characteristics 
were significantly associated with predictive ability. City-level characteristics were calculated 
using the RDS-II estimator13 which should provide an unbiased estimate of the underlying target 
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population but we are unable to verify that these RDS-weighted estimates are reflective of our 
target population (i.e., PWID in each city).  
 
These results add to our prior work highlighting the rapid identification of key populations in 
India using RDS9 by also showing that recruitment has identifiable patterns. This suggests the 
potential to leverage RDS in order to efficiently identify the large fraction of those PWID that 
are HIV-infected but unaware of their infection and viremic, thus working towards the 90-90-90 
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Table 3.1 Characteristics of recruiting an undiagnosed PLWH and their predictive accuracy 









Odds Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds Ratio‡ 95% CI 
n (row %)/ 
median 
(IQR) 
n (row %)/ 
median 
(IQR) 











































































0.93 - 1.76 
0.30 - 0.67 
0.01 - 0.10 
1.13 - 2.09 
0.13 - 0.38 
1.57 - 3.15 
 
1.17 - 2.16 
0.86 - 1.63 
1.27 - 2.32 
1.41 - 2.57 
 
0.09 - 0.29 
1.07 - 1.99 
3.33 - 5.76 
0.38 - 0.82 
0.711 0.698 - 0.725 -- 
 
Age, years (model by 10 
years) 29 (24-36) 30 (25-37) 1.13 1.06 - 1.21 0.537 0.520 - 0.553 1.28 1.17 - 1.39 













0.50 - 0.89 
* 





0.43 - 0.80 
* 
Marital status          
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Odds Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds Ratio‡ 95% CI 
n (row %)/ 
median 
(IQR) 























0.76 - 0.97 
 
0.88 - 1.25 






0.71 - 0.93 
 
0.71 - 1.04 
Education          
No/primary school 
Secondary school 















0.63 - 0.81 
 
0.52 - 0.73 






0.66 - 0.85 
 
0.58 - 0.82 













1.89 - 2.42 
* 
0.572 0.558 - 0.585 -- 
 








2.62 2.33 - 2.95 0.618 0.604 - 0.632 --  
HIV/HCV status          

























1.30 - 2.20 
 
2.05 - 2.71 
3.10 - 4.18 







1.44 - 2.48 
 
1.91 - 2.56 
2.86 - 3.94 
Injection duration, years 
(model by 5 years) 6 (3-12) 7 (3-12) 1.01 0.97 - 1.05 0.508 0.491 - 0.524 0.86 0.82 - 0.91 
Shared needle/syringe in 








1.40 1.24 - 1.57 0.539 0.525 - 0.553 
Reference 
1.17 1.44 - 1.32 
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Odds Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds Ratio‡ 95% CI 
n (row %)/ 
median 
(IQR) 




program use in past 6 










1.30 1.16 - 1.46 0.531 0.517 - 0.545 
Reference 
1.09 0.97 - 1.24 
Opioid agonist therapy in 








1.02 0.88 - 1.19 0.502 0.491 - 0.512 
Reference 
0.89 0.76 - 1.05 
PWID network size†          
≤8 
9 to 20 















1.24 - 1.74 
1.31 - 1.85 
1.46 - 2.07 





1.11 - 1.56 
1.12 - 1.60 
1.19 - 1.72 
PLWH: person who injects drugs living with HIV; IQR: interquartile range; CI: confidence interval; AUROC: area under the receiver operator curve; HCV: Hepatitis C virus; PWID: person who injects 
drugs 





















1 Age, gender, marital status, 
education (demographics) 
0.575  
(0.558 - 0.591) 
0.563 
(0.549 - 0.577) 
Age ≥30, male, never married, 
and no/primary education  
15.1% 19.1% 
2 HIV/HCV infection status 




(0.636 - 0.663) 
HIV/HCV co-infected and 
network size ≥51 
18.8% 28.1% 
3 HIV/HCV infection status, 
network size, and recent 
needle/syringe sharing 
0.644 
(0.638 - 0.660) 
0.649 
(0.636 - 0.663) 
HIV/HCV co-infected, network 
size ≥51, and recently shared 
needle/syringe 
24.7% 33.8% 
4 Recent needle/syringe 
sharing, NEP, OAT 
0.559 
(0.543 - 0.574) 
0.559 
(0.546 - 0.573) 
Recently shared needle/syringe, 
used NEP, did not use OAT 
10.7% 15.0% 
5 Demographics, HIV/HCV 
infection status, network 
size, injection duration, 
recent needle sharing, NEP, 
OAT 
0.666 
(0.651 - 0.682) 
0.661 
(0.647 - 0.674) 
Age ≥30, male, never married, 
no/primary education, HIV/HCV 
co-infected, network size ≥51, 
injecting for ≥5 years, recently 
shared needle/syringe, used NEP, 
and did not use OAT. 
9.1% 18.2% 
PLWH: people who inject drugs living with HIV; AUROC: area under the receiver operator curve from logistic regression model; NEP: needle/syringe exchange program; OAT: 
opioid agonist therapy 
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Table 3.3 Bootstrapped multivariable prediction of recruiting an undiagnosed/viremic PLWH by city and city-level characteristics 
 Northeast Region North Region Central Region 




0.522 0.592 0.605 * 0.579 0.555 * 0.602 0.583 0.542 0.547 0.500 0.664 0.607 0.543 


























PLWH 0.563 0.617 0.576 0.769 0.624 0.620 * 0.618 0.584 0.548 0.544 0.546 0.654 0.613 0.602 



























City-level characteristics (%)1 
Median age (years) 27.7 30.3 30.5 28.9 34.5 25.1 33.2 28.6 30.7 32.6 29.4 32.8 28.7 34.6 33.1 
Female 18.7 22.7 14.1 6.7 12.3 12.1 23.2 1.2 0.4 0.0 0.2 0.1 0.5 0.7 3.5 
At least secondary 
school education 93.8 73.4 66.5 82.7 71.1 95.1 60.6 58.0 66.2 30.7 66.1 68.0 69.9 36.7 38.6 
Annual HIV 
incidence 1.65 1.86 1.68 0.21 0.56 0.64 4.43 5.95 1.75 7.81 3.72 0 4.29 15.69 1.06 
HIV prevalence 25.4 22.4 21.7 11.2 31.1 11.5 44.9 21.1 10.5 13.8 18.1 5.9 8.9 30.9 8.6 
Aware of HIV+ 
status2 61.8 36.0 81.6 92.8 38.8 60.1 66.8 40.8 19.6 17.8 25.8 70.3 16.6 2.4 54.6 
Linked to HIV 
care2 34.0 27.1 58.2 46.0 18.8 37.8 49.2 5.4 4.4 1.7 12.1 60.3 1.7 1.3 30.0 
ART use among 
eligible3 28.3 49.4 60.7 60.6 31.9 47.6 53.8 9.9 9.3 7.3 15.3 74.6 3.7 0.0 38.5 
Undetectable viral 
load among ART 
eligible3 
29.5 57.7 52.3 68.6 38.5 60.8 50.9 8.3 27.3 1.5 19.8 65.8 1.2 1.7 30.2 
HIV viremia4 18.8 11.4 11.0 3.4 18.8 5.2 24.7 19.7 8.9 13.5 15.5 2.7 8.0 29.7 7.6 
Ever tested for 
HCV 27.2 11.8 3.6 5.9 16.5 9.1 18.8 9.2 1.6 3.2 4.0 2.3 0.7 0.2 5.5 
HCV Ab+ 
prevalence 64.4 50.4 9.1 4.9 64.9 15.3 41.1 48.7 51.1 42.4 25.7 7.8 22.3 63.6 34.1 
Aware of HCV+ 
status5 17.4 6.2 5.5 29.7 11.7 6.1 9.2 7.3 1.4 1.5 1.8 3.1 0.1 0.6 2.9 
Ever NEP use 53.0 44.5 13.5 36.2 28.0 36.1 53.0 38.9 23.8 42.1 59.2 44.3 7.7 6.8 73.8 
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Ever OAT 23.7 10.8 11.8 6.5 33.0 6.4 12.9 43.3 23.7 27.1 19.0 25.1 0.0 6.4 48.7 
Ever shared 
needle/syringe 46.7 52.8 20.2 36.8 71.0 30.7 31.3 40.0 29.5 32.3 19.8 25.6 16.4 69.1 31.6 
Injection drug use 
in prior 6 mo. 92.0 98.5 68.3 83.2 98.2 91.5 88.2 87.3 83.0 97.4 80.3 91.1 95.7 99.1 89.2 
PLWH: person who inject drugs living with HIV; AZ: Aizawl; CR: Churchandpur: DM: Dimapur; GT: Gangtok; IM: Imphal; LG: Lunglei; MO: Moreh; AM: Amritsar: CD: Chandigarh: DL: New 
Delhi; BE: Bhubaneshwar; BI: Bilaspur: KA: Kanpur: MU: Mumbai. 
*In one or more bootstrapped samples, no individuals had the outcome of interest thus the AUROC could not be calculated. 
AUROC: area under the receiver operator curve from logistic regression; CI: confidence interval; ART: antiretroviral therapy; HCV: Hepatitis C virus; Ab+: antibody positive; NEP: needle/syringe 
exchange program; OAT: opioid agonist therapy 
1: All city-level characteristics are RDS-II weighted with the exception of annual HIV incidence; 2: Among those HIV-infected; 3: Among those HIV-infected and CD4 count<350 or self-reported prior 





Supplementary Table 3.1 Characteristics of recruiting a viremic PLWH and their predictive accuracy 
 










Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds 
Ratio‡ 95% CI 
n (row %)/ 
median (IQR) 
n (row %)/ 
median (IQR) 











































































0.48 - 0.78 
0.29 - 0.50 
0.06 - 0.15 
0.65 - 1.03 
0.10 - 0.21 
1.03 - 1.73 
 
0.63 - 0.99 
0.34 - 0.57 
0.53 - 0.85 
0.62 - 0.98 
 
0.08 - 0.18 
0.44 - 0.72 
1.19 - 1.81 
0.25 - 0.44 
0.678 0.666 - 0.690 -- 
 
Age, years (model by 10 years) 29 (24-35) 30 (25-37) 1.16 1.10 - 1.22 0.544 0.530 - 0.558 1.16 1.08 - 1.26 













0.92 - 1.38 
* 




0.76 - 1.18 
* 
Marital status          
Never married 




















0.88 - 1.09 
 
1.16 - 1.56 







0.82 - 1.04 
 
0.89 - 1.23 
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Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds 
Ratio‡ 95% CI 
n (row %)/ 
median (IQR) 
n (row %)/ 
median (IQR) 
Education          
No/primary school 
Secondary school 















0.72 - 0.90 
 
0.63 - 0.84 






0.74 - 0.93 
 
0.70 - 0.94 














2.22 - 2.75 
* 
0.586 0.574 - 0.597 -- 
 










2.32 - 2.83 0.615 0.603 - 0.627 --  
HIV/HCV status          


























1.93 - 2.90 
 
2.06 - 2.63 
3.44 - 4.47 









1.89 - 2.90 
 
1.88 - 2.42 
3.06 - 4.04 
Injection duration, years (model 
by 5 years) 6 (3-12) 7 (3-13) 1.07 1.03 - 1.11 0.533 0.519 - 0.547 0.93 0.89 - 0.97 
Shared needle/syringe in past 6 














1.00 - 1.24 
Needle/syringe exchange 
program use in past 6 months    
 














1.05 - 1.30 
Opioid agonist therapy in past 6 
months         
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Ratio 95% CI AUROC 95% CI 
Adjusted 
Odds 
Ratio‡ 95% CI 
n (row %)/ 
median (IQR) 















0.91 - 1.20 
PWID network size†          
≤8 
9 to 20 














1.24 - 1.65 
1.29 - 1.74 
1.57 - 2.11 





1.08 - 1.45 
1.06 - 1.43 
1.17 - 1.60 
PLWH: person who injects drugs living with HIV; IQR: interquartile range; CI: confidence interval; AUROC: area under the receiver operator curve; HCV: Hepatitis C virus; PWID: person who injects 
drugs 
‡Adjusted for all other covariates listed below; *Predicted the outcome perfectly and was thus dropped from the regression model; †Number of PWID they personally know in their city, categorized by 
quartile
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Chapter 4: Identifying undiagnosed HIV-infected people who inject drugs using 
respondent-driven sampling 
 
Allison M. McFall1, Bryan Lau1, Carl Latkin1, Aylur K. Srikrishnan2, Santhanam Anand2, 
Canjeevaram K. Vasudevan2, Shruti. H. Mehta1, Sunil S. Solomon3 
 
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 2YR Gaitonde Centre for AIDS Research and 




Background People who inject drugs (PWID) experience a high HIV burden and lag behind in 
meeting the UNAIDS 90-90-90 continuum target, particularly at diagnosis. In prior work, 
respondent-driven sampling (RDS), a type of chain referral sampling, rapidly identified 
undiagnosed HIV-infected PWID in India. The objective of this paper is to evaluate whether the 
efficiency of identification of undiagnosed HIV-infected PWID in India can be further enhanced 
through alterations to the RDS coupon system. 
 
Methods First, we identified characteristics that predict recruitment of an undiagnosed HIV-
infected PWID into an RDS, using RDS data from 4,002 PWID in four north Indian cities in 
2013. The area under the receiver operator curve (AUROC) from logistic regression models and 
a random forest were used to identify predictors and a multivariable prediction model was built. 
An altered coupon system was tested using RDS data from 1289 PWID in Morinda, Punjab. 
RDS participants were randomly assigned (1:1) to a normal or altered coupon system. In the 
normal system, PWID received 2 recruitment coupons. In the altered system, the prediction 
model determined their likelihood of recruiting an undiagnosed HIV-infected PWID; those likely 
received 5 coupons, those unlikely received 2 coupons. The number needed to recruit (NNR) - 
average number of individuals recruited in order to find one undiagnosed individual - for recruits 
of each coupon system was used to compare the efficiency of the two systems. 
 
Results Predictors of recruiting an undiagnosed HIV-infected PWID identified by the AUROCs 
and random forest included HIV/HCV infection, PWID network size, utilization of 
needle/syringe exchange programs, and the injection environment - where PWID and with whom 
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they inject. In Morinda, median age of the sample was 27, all were men, and 22% injected daily. 
HIV prevalence was 11%, of whom 66% were previously undiagnosed. Among recruits, 643 
were randomized to the normal system, from which 475 PWID were recruited, including 29 
undiagnosed; 646 were randomized to the altered coupon system, from which 810 were 
recruited, including 65 undiagnosed. The NNR for the normal coupon system was 16.4 compared 
to an NNR of 12.5 for the altered system (difference=3.9, 95% CI: -1.6 to 13.1). 
 
Conclusions An altered RDS coupon system in which individuals more likely to recruit 
undiagnosed HIV-infected PWID were provided more recruitment coupons did not significantly 
improve the efficiency of identification of undiagnosed PWID over the normal/traditional 





Diagnosis is the first step in the HIV care continuum and is required in order to link people living 
with HIV (PLWH) to the care and treatment they need1. The importance of this step to individual 
and community benefit is highlighted in the UNAIDS 90-90-90 target to help end the global 
AIDS epidemic by 2020 - 90% of PLWH diagnosed, 90% of those diagnosed receiving sustained 
antiretroviral therapy (ART), and 90% of those on ART virally suppressed 2. Along with 
maximizing evidence-based prevention efforts, treating a large majority of PLWH will avert new 
infections. All of this must occur in a human rights framework, including respecting the unique 
needs of key populations such as men who have sex with men (MSM), people who inject drugs 
(PWID), and sex workers. For these populations, structural factors such as stigma, 
discrimination, and criminalization often make accessing HIV prevention and care services 
difficult thus leading to large gaps in the continuum - particularly at diagnosis3. Among PWID in 
India, we previously found only 40% of those HIV-infected were aware of their infection, well 
behind the 90% target4. 
 
Narrowing these gaps and meeting the UNAIDS first 90 target (HIV diagnosis) will require new 
approaches to reach those not currently engaged in HIV testing services. Looking to existing 
tools and investigating how to leverage or alter them to identify more undiagnosed PLWH is a 
good first step, especially given our current landscape of limited or declining investment and 
resources. Respondent-driven sampling (RDS), a type of chain-referral sampling, is commonly 
used in public health for HIV surveillance and research among key populations for which a 
sampling frame does not exist5. Using recruitment coupons distributed to peers, RDS leverages 
social network connections to recruit study participants, rather than utilizing study staff to 
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identify and recruit potential participants. While the resulting sample is most likely biased, 
specifically designed estimators can weight estimates to provide unbiased population estimates 
such as HIV prevalence. Recently, several have noted the potential of RDS to be used beyond 
surveillance or measuring population characteristics to an implementation tool or intervention to 
quickly reach and engage individuals at high-risk for HIV6-9. In prior work, we found RDS 
rapidly identified PWID in India, including many that were HIV-infected but previously 
undiagnosed or viremic - individuals not engaged in traditional HIV services such as clinic-based 
HIV testing and care or outreach services10. Given the potential of RDS to be used as a strategy 
to improve levels of diagnosis among PLWH, the overall objective of this paper is to evaluate 
whether the efficiency of identification of undiagnosed HIV-infected PWID in India can be 




The evaluation of an altered RDS coupon system was conducted in Morinda, Punjab, located in 
the northern region of India. To design the altered system, we first identified characteristics that 
predict recruitment of an undiagnosed HIV-infected PWID into an RDS. Since there is 
significant regional variation in HIV prevalence and incidence, care continuum outcomes, and 
injection drug use characteristics across India, RDS data from sites in northern India included in 
a prior study were used to build a prediction model. This model was then used to determine 
differential coupon distribution in the evaluation of the altered RDS coupon system in Morinda. 
Detailed methods are described below. 
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Predicting recruitment of an undiagnosed HIV-infected PWID 
Study design and procedures 
To identify characteristics that predict recruitment of an undiagnosed HIV-infected PWID, data 
from the National Collaboration on AIDS (NCA) trial (ClinicalTrials.gov identifier: 
NCT01686750) were used. The NCA trial is a cluster-randomized trial among MSM and PWID 
in India investigating the community effectiveness of integrated care centers (ICCs) on the 
uptake of HIV testing as previously described11. Population-level effectiveness was assessed 
using two community cross-sectional samples collected via RDS before and after 
implementation of ICCs. Data for this analysis were restricted to the pre-intervention (or 
baseline) data collected from four cities located in northern India in the PWID stratum of the trial 
(Amritsar, Ludhiana, Chandigarh, and New Delhi) (Figure 1).  
 
Participants were recruited using RDS between January and July 2013. Two seeds, individuals 
considered to be well-connected and influential in the local PWID community, initiated 
recruitment in each city. Each seed received two recruitment coupons to distribute randomly to 
others they know inject drugs in the community. Individuals that received a coupon, voluntarily 
visited the study center, and if eligible, were enrolled, completed study procedures, and received 
two recruitment coupons to distribute to their network at random. Recruitment continued until 
the desired sample size in each city was met (~1000 recruits). Coupons were bar-coded with 
identification numbers to link recruiters and their recruits and included a hologram to prevent 
duplication of coupons. Eligibility criteria to enroll in the study included (1) being at least 18 
years old, (2) provision of informed consent, (3) possession of a valid coupon unless a seed, and 
(4) self-reported injection drug use in the prior 24 months. Dual compensation was provided for 
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study participation and recruitment. Study participants received INR 250 (US $3.8) for 
completing study procedures and INR 50 (US $0.80) for each eligible study participant they 
recruited into the study. 
 
After informed consent was obtained, study participants provided a blood sample and completed 
an interviewer-administered questionnaire that collected socio-demographics, HIV and HCV 
testing and care history, injection and sexual HIV risk behaviors, harm reduction services 
utilization, and network characteristics. HIV pre- and post-test counseling in addition to 
appropriate referrals to care for HIV-infected participants were provided with rapid onsite HIV 
testing. HIV testing was conducted in accordance with Indian guidelines using 3 rapid tests: 
Alere Deterimine 1/2 (Alere Medical, Chiba, Japan), First Response HIV Card Test 1-2.0 
(Premier Medical Corporation, Daman, India), and Signal Flow Through HIV 1+2 
Spot/Immunodot Test Kit (Span Diagnostics, Surat, India). HIV-1 RNA (viral load) 
quantification was conducted for all HIV-infected participants using Abbott RealTime HCV 
assay (Abbott Laboratories, Abbott Park, Illinois, US). Hepatitis C (HCV) antibody testing was 
conducted on stored blood samples using Genedia HCV ELISA 3.0 (Green Cross Medical 
Science, Chungbuk, Korea). 
 
Statistical methods 
NCA study participants were categorized as undiagnosed if positive by the rapid HIV tests and 
self-reported no prior diagnosis. For each participant, we determined whether they recruited an 
undiagnosed PWID into the RDS - the main outcome of interest - using the linkage between 
recruiters and their recruits in the data. If a participant recruited at least one undiagnosed PWID 
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out of their enrolled recruits, they were considered to have the outcome of interest (Y=1) and 
participants that recruited no undiagnosed PWID or had no recruits at all did not have the 
outcome (Y=0). Characteristics that predict recruitment were identified using two methods: 
logistic regression models and a random forest. Characteristics investigated included HIV 
infection status as well as those shown to be associated with HIV risk among PWID in the 
literature including socio-demographics, HCV infection status, sexual and injection drug use risk 
behaviors, and network size. In total, the predictive ability of more than 50 characteristics were 
explored. 
 
Univariable logistic regression models were conducted for each characteristic of interest and the 
area under the receiver operator curve (AUROC) was calculated to discriminate between those 
that do and do not recruit undiagnosed HIV-infected PWID. AUROCs were calculated using a 
10-fold cross-validation technique to address over fitting of the model12. To briefly describe this 
technique, the full data were randomly divided into ten evenly sized groups; one group was left 
out as the validation set and the logistic model was run on the remaining nine groups (i.e., the 
training group). Model coefficients were then applied to the validation set data. This is repeated 
so that each group was in the training group nine times and the validation data once. Predicted 
probabilities from the validation model were used to calculate the overall AUROC.  
 
In addition to the regression models, a random forest was built to assess characteristics’ 
predictive ability. Briefly, a random forest is a machine learning algorithm that can be used for 
regression (i.e., continuous outcome) or classification (i.e., categorical outcome) purposes13. For 
this analysis, we used classification since the outcome is dichotomous. First, a bootstrapped 
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sample with replacement of the full data set was conducted; this new data set is known as the in-
bag data. With the in-bag data, a decision tree was constructed using a random selection of 
variables at each node of the tree starting at the root node (number of candidate variables 
assessed at each node=√m, where m=number of total predictor variables); the variable with the 
best split was chosen and splits continued to occur until a decision node resulted in a completely 
homogenous sample (i.e., all observations have the same classification). A large number of 
decision trees are often made with the in-bag data, generally hundreds, hence the term forest. 
Then, each observation in the out-of-bag data (i.e., those not in the in-bag data) was run down 
each tree which gave a predicted classification (i.e., vote). The classification with the most votes 
across the trees was the classification for that observation and with this information, an error rate 
for the out-of-bag classification can be calculated. Variable importance (VIMP) can be 
calculated for each characteristic, which represents how much removing the characteristic 
reduces the accuracy of the model - or increases the error rate. The random forest constructed for 
predicting recruitment of an undiagnosed HIV-infected PWID included 56 different 
characteristics and 500 trees. The best split at each node in the tree was determined by the Gini 
index. Variable importance was calculated for each characteristic using the permutation 
method13. 
 
A multivariable prediction model was built that included characteristics with an AUROC>0.5 
from the univariable logistic regression or a VIMP>0 from the random forest. An overall 
AUROC was calculated for the prediction model to determine its ability to discriminate between 
those that do and do not recruit an undiagnosed HIV-infected PWID. For the altered RDS 
coupon system in Morinda, a cut-point in predicted probability calculated from the prediction 
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model was required to divide the sample into two groups: 1) likely to recruit an undiagnosed 
HIV-infected PWID and 2) unlikely to recruit an undiagnosed HIV-infected PWID. Sensitivity 
and specificity of the probabilities were calculated to assess the ideal cut-point which was chosen 
so that sensitivity was optimized while ensuring specificity was at least 0.5. 
 
Evaluating alterations to the RDS recruitment coupon system 
Study design and procedures 
To evaluate whether the efficiency of identification of undiagnosed HIV-infected PWID can be 
enhanced through alterations to the RDS coupon system, data were collected as a part of a study 
designed to identify cost-effective network and geospatial strategies to identify PWID across 
several different Indian cities. For this analysis, we used data from Morinda, Punjab, a small city 
located in northern India and situated on the main road connecting Chandigarh and Ludhiana 
(Figure 1). In Morinda, we evaluated a targeted time-based RDS (ttRDS) strategy, a variation of 
RDS in which RDS was allowed to run for a year, regardless of sample size accrued, and a 
targeted or altered RDS recruitment coupon system was implemented and compared to a normal 
coupon system in terms of the systems’ efficiency of identification of undiagnosed HIV-infected 
PWID. 
 
In December 2017, two seeds initiated recruitment in Morinda and each received two recruitment 
coupons to distribute randomly to others they know inject drugs in the community. Then 
beginning at the first wave of recruitment and beyond (i.e., recruits of the seeds, recruits of wave 
1, etc.), individuals were randomized to one of two arms, the normal coupon system or the 
altered coupon system, in a 1:1 allocation (Figure 2). Prior to implementation, a randomization 
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list was made with blocks of varying sizes (8 to 16). If randomized to the normal coupon system, 
they received two recruitment coupons to distribute to their network. If randomized to the altered 
coupon system, a software program extracted the individual’s specific questionnaire responses 
from the interview as well as the rapid HIV and HCV test results into the prediction model 
(multivariable logistic regression model including all characteristics with AUROC>0.5 or 
VIMP>0 as described above) and calculated the predicted probability of recruiting an 
undiagnosed HIV-infected PWID. If the predicted probability was below the cut-point (cut-point 
determined as previously described above) the person received two recruitment coupons to 
distribute to their network, and if greater than or equal to the cut-point, they received five 
recruitment coupons.  
 
As in the NCA trial, coupons were bar-coded with identification numbers to link recruiters and 
their recruits and included a hologram to prevent duplication of coupons. Eligibility criteria to 
enroll in the study was the same as the NCA trial with the exception of the last criterion: self-
reported injection drug use in the prior 12 months (as opposed to 24 months for the NCA trial). 
The same dual compensation was provided for study participation and recruitment as in the NCA 
trial. A biometric system was used to track duplicate enrollments into the RDS as well as identify 
individuals that were clients of nearby ICCs and/or participated in our prior RDS samples in the 
region in 2016-2017. Clients’ fingerprints were scanned then converted into unique 




Following consent, study participants provided a blood sample and completed an interviewer-
administered questionnaire that collected socio-demographics, HIV and HCV testing and care 
history, injection and sexual HIV risk behaviors, harm reduction service utilization, and network 
characteristics. HIV/HCV pre- and post-test counseling with appropriate referrals to care for 
infected participants were provided with rapid onsite HIV and HCV testing. HIV testing was 
conducted in accordance with Indian guidelines using 3 rapid tests as in the NCA trial. Onsite 




Preliminary data available through September 11, 2018 were analyzed. For exploratory data 
analyses, overall sample characteristics, recruit characteristics by coupon system and number of 
recruitment coupons received, and RDS process measures are described including total number 
of recruitment waves and coupon return rate. Statistical comparisons of characteristics between 
groups used chi-squared tests for categorical variables and the Wilcoxon rank-sum test for 
continuous variables.  
 
The number needed to recruit (NNR) in order to find one undiagnosed individual (total number 
recruited / number of undiagnosed PWID identified) was used to compare the efficiency of the 
two coupon systems - normal vs. altered - in identifying undiagnosed HIV-infected PWID. The 
lower the NNR, the more efficient a system. The NNR was calculated for the recruits of each 
coupon system. Using the link between recruiter and recruit in the data, we identified each study 
participant’s recruiter and which arm they were in. Then, the NNR was calculated for the recruits 
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of each coupon system (excluding wave 1 participants since their recruiters were seeds). The 
difference in the NNR between the two systems was calculated and a confidence interval around 
the difference was estimated using a bootstrap method. For the recruits of each coupon system 
separately, 1000 samples with replacement of the data were taken. For each sample, the NNR for 
each arm was calculated and the resulting NNR difference. The 2.5th and 97.5% percentile of the 
1000 NNR differences represent the 95% confidence interval. As a secondary analysis, we 
explored the NNR over time, by month of active cumulative recruitment, for the two coupon 
systems. As an additional efficiency measure, we calculated the identification rate, which is the 
average number of undiagnosed individuals identified per week (total number of undiagnosed 
HIV-infected PWID identified / total number of weeks RDS recruitment was active), by 
recruiter’s coupon system. The confidence interval for the difference in identification rate 
between the two systems was calculated using a bootstrap method similar to the one used for the 
NNR difference as described above. 
 
Analyses were conducted using Stata (StataCorp. 2017. Stata: Release 15. Statistical Software. 
College Station, TX: StataCorp LLC) with the exception of the random forest and VIMP 
calculation in which the package randomForestSRC in R was used (R Core Team (2016). R: A 
language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL https://www.R-project.org/). P-values were considered statistically 




This study was approved by the institutional review boards of Johns Hopkins University School 
of Medicine and the Y.R. Gaitonde Centre for AIDS Research and Education. 
 
RESULTS 
Predicting recruitment of an undiagnosed HIV-infected PWID 
A total of 4,002 study participants were recruited across the four north NCA trial sites. Median 
age was 28 (interquartile range [IQR]: 23 - 35), nearly all were male (99.7%), 52.6% were never 
married, 7.6% were widowed/divorced/separated, and 45.4% had a primary education or less. 
More than half were injecting daily (52.3%) and of those actively injecting in the prior months, 
79.7% reported injecting buprenorphine, the most commonly used drug. HIV prevalence among 
the sample was 18.5%; 72.8% of those infected were previously unaware of their status. HCV 
prevalence was 46.8%. The overall coupon return rate was 50.1%; 42.2% recruited no 
participants into the RDS, 15.9% recruited one PWID, and 42.0% recruited two PWID into the 
RDS. Among all study participants, 12.1% recruited at least one undiagnosed HIV-infected 
PWID. 
 
Characteristics of recruiting an undiagnosed HIV-infected PWID are presented in Table 4.1 
along with their predictive accuracy calculated from univariable logistic regressions (i.e., 
AUROC) and the random forest (i.e., VIMP). The larger an individual’s PWID network size, the 
more likely they were to recruit an undiagnosed PWID (by an increase of one ln OR: 1.10, 95% 
CI; 1.03 - 1.18); network size had the highest AUROC (0.534). Compared to those HIV and 
HCV negative, PWID with mono-HCV infection (OR: 1.38, 95% confidence interval [CI]: 1.11 - 
1.71) and co-infection (OR: 1.78, 95% CI: 1.37 - 2.31) were significantly more likely to recruit 
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an undiagnosed PWID; HIV/HCV status had the second highest AUROC (0.531). Other 
characteristics with an AUROC>0.5 included the number of sexual partners in the prior six 
months (AUROC=0.509), injecting buprenorphine in the prior six months (AUROC=0.510), 
injecting in a shooting gallery in the prior six months (AUROC=0.504) and using a 
needle/syringe exchange program (NEP) in the prior six months (AUROC=0.522). 
Demographics - age, sex, marital status, and education - were not significantly associated with 
recruiting an undiagnosed PWID. HIV/HCV status, NEP use, and injecting in a shooting gallery 
also had VIMP scores above one. Characteristics with VIMP scores above one but that did not 
have an AUROC>0.5 include injecting sedatives (VIMP=0.000638) and stimulants 
(VIMP=0.000134) in the prior six months, injecting with multiple people (VIMP=0.000447) and 
sexual partners (VIMP=0.000179) in the prior six months, being incarcerated in the prior six 
months (VIMP=0.000134), injecting at a friend’s house (VIMP=0.000134), public toilet 
(VIMP=0.000045) or other place (VIMP=0.000078) in the prior six months, and being female 
(VIMP=0.000022).  
 
The multivariable model including only characteristics with an AUROC>0.5 resulted in an 
AUROC of 0.573 (Table 4.2); adding the characteristics identified by the random forest with a 
VIMP>0 increased the AUROC to 0.575. Figure 3 plots the sensitivity and specificity of 
probability cut-offs from the multivariable model including all characteristics with an 
AUROC>0.5 or VIMP>0 (i.e., the final prediction model used for evaluating the altered RDS 
coupon system in Morinda). A probability cut-off of approximately 0.11 results in a sensitivity of 
0.65 and specificity of 0.50 and therefore was chosen as the cut-off to be used in Morinda. This 
cut-off results in a positive predictive value of 0.16 and negative predictive value of 0.92. 
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Evaluating alterations to the RDS recruitment coupon system 
As of September 11, 2018, 1289 PWID recruits were enrolled and completed study procedures in 
Morinda. Median age was 27 (IQR: 22 - 33), all were men, 21.5% were injecting daily and 
among those injecting in the prior six months, the most commonly used drug was buprenorphine 
(77.5%). HIV prevalence was 11.0% and 66.2% of those HIV-infected were previously unaware 
of their infection. HCV prevalence was 44.8% and HIV/HCV co-infection was 9.8%. Forty 
(3.1%) had a biometric match to an ICC client, nearly all in Chandigarh (n=38) and 31 (2.4%) 
matched to a recent RDS participant, nearly all in Chandigarh (n=29).  
 
Among recruits, 643 were randomized to the normal coupon system and 646 were randomized to 
the altered coupon system. Characteristics were similar across the two arms/coupon systems 
(Table 4.3). Of those in the altered system, 307 (47.5%) had a predicted probability less than 
0.11 and received two recruitment coupons; 339 (52.5%) had a predicted probability of at least 
0.11 and received 5 coupons. Applying the prediction model built using the NCA trial data to the 
RDS data in Morinda, the AUROC was 0.621 (95% CI: 0.570 - 0.672), suggesting good 
predictive ability. 
 
Recruitment progressed to 17 waves. Most participants were generated from one of the seeds 
(97.6%) (Figure 4). The overall coupon return rate was 35.7% and did not differ across study 
arms/coupon systems (normal coupon system arm=36.9%, altered coupon system arm=35.1%, 
altered-two coupon=36.0%, altered-five coupon=34.7%). On average, those that received two 
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coupons (in either arm), recruited 0.7 participants. For those in the altered arm that received 5 
coupons, they recruited 1.8 participants on average.  
 
From the normal coupon system, a total of 475 PWID were recruited and from the altered 
system, a total of 810 were recruited. There were no significantly different characteristics across 
the recruits of the two coupon systems (Table 4.3). Within recruits of the altered system, there 
were some significant differences between participants that were recruited by those determined 
to be less likely to recruit an undiagnosed PWID (i.e., predicted probability<0.11 and received 2 
coupons) and those determined to be more likely to recruit an undiagnosed PWID (i.e., predicted 
probability≥0.11 and received 5 coupons). Recruits of those that received 5 coupons were more 
likely to have been tested for HIV in the prior year (39.7% vs. 22.6%, p<0.001) and use a 
needle/syringe exchange program (36.7% vs. 28.1%, p=0.021) or opioid agonist therapy (31.2% 
vs. 20.4%, p=0.002) in the prior six months. When compared to recruits of those randomized to 
normal coupon system that had a predicted probability≥0.11 (i.e., would have received more 
recruitment coupons had they been randomized to the altered system), recruits of those that 
received 5 coupons were similar across all characteristics explored with the exception of number 
of sexual partners in the prior six months. Recruits of those that received 5 coupons were more 
likely to have 1 sexual partner (52.1% vs. 42.9%, p=0.022) (Supplementary Table 4.1). 
 
A total of 29 undiagnosed HIV-infected PWID were recruited from the normal system, resulting 
in an NNR of 16.4. A total of 65 undiagnosed PWID were recruited from the altered system, 
resulting in an NNR of 12.5. The difference in NNR was 3.9 but the confidence interval overlaps 
zero (95% CI: -1.6 to 13.1), therefore the difference is not statistically significant. Plotting the 
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NNR over recruitment months suggests that the normal coupon system NNR generally decreased 
over time while the altered coupon system NNR seemed to be more stable (Supplementary 
Figure 4). At each time point the difference in NNR between the two systems was not 
statistically significant (i.e., confidence interval of difference overlapped zero). The 
identification rate of undiagnosed HIV-infected PWID for the altered system was higher 
(1.7/week) than the normal system (0.8/week) (difference: 0.9, 95% CI: 0.4 - 1.4). 
 
DISCUSSION 
An altered RDS coupon system in which individuals more likely to recruit undiagnosed HIV-
infected PWID were provided more recruitment coupons did not significantly improve the 
efficiency of identification of undiagnosed PWID over the traditional coupon system. 
Characteristics such as HIV and HCV infection, PWID network size, utilization of 
needle/syringe exchange programs, and the injection environment - where PWID and with whom 
they inject - predicted who was more likely to recruit undiagnosed PWID. However, 
characteristics’ predictive ability was generally quite low, suggesting recruitment and/or the 
network composition among our target population did not have strong enough patterns to steer an 
RDS to more efficiently identify undiagnosed PWID.  
 
On the other hand, the number of undiagnosed PWID identified each week was significantly 
higher for the altered coupon system, finding almost one additional undiagnosed person each 
week over the normal system and more than twice as many in total over the full recruitment 
period of 10 months. This was a consequence of more coupons given and recruits enrolled from 
the altered system. Increasing the number of recruitment coupons more rapidly identified PWID 
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overall, which often results in RDS recruitment trees that grow out (or wide), rather than down. 
This may result in samples that do not reach deeper into the network, not reaching those more 
peripheral that have different risk profiles from the seeds or earlier waves, which would have 
consequences for the ability of the sample to provide unbiased population estimates14. However, 
recruits of the two systems did not differ on key risk behaviors or other characteristics and, 
importantly, the goal of the altered system was to increase the efficiency of identifying 
undiagnosed HIV-infected PWID, not estimate population characteristics. Statistical methods 
that take data from an RDS sample that has been deliberately steered to a particular sub-group 
and estimate population characteristics such as HIV prevalence should be an area of future 
research. 
 
There is little prior research on differential coupon distribution in order to steer an RDS sample 
to preferentially recruit specific sub-groups. Among PWID in Tijuana, Mexico, researchers 
provided more coupons to women in order to recruit more women but were not successful15; 
notably, this strategy assumes women who inject drugs are connected to other women, which 
may not be the case. Similar to differential coupons, researchers have increased participant 
compensation for recruiting more of a particular sub-group such as younger PWID14 or 
individuals at high risk for HIV16 in the United States, with the former but not the latter being 
successful. In Tajikistan, Kan and colleagues compared a traditional RDS design in which 
recruitment of PWID continued indefinitely to a system in which recruitment ceased after two 
waves with no HIV-infected PWID in terms of the approaches’ ability to identify new HIV 
diagnoses; the restricted RDS approach yielded more new diagnoses17  
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It is important to note that Morinda is a smaller community compared to the others that we have 
previously conducted RDS samples in for the NCA trial, likely with a smaller total population 
size of PWID. There are currently approximately 400 PWID registered at the local OAT center 
(per personal communication), so with over 1200 total PWID recruited, we may have sampled a 
large fraction of PWID in Morinda and its surrounding communities. This may have impacted 
our ability to see a meaningful and/or statistically significant difference between the two coupon 
systems. To investigate possible implications, future work will explore the geographical reach of 
the RDS using pin code as well as calculate PWID population size estimates. 
 
There are limitations to this work that should be noted. First, the evaluation was conducted in 
one city in India. Replicating this or a similar approach in additional communities with different 
HIV and injection drug use epidemics would provide more robust evidence on the efficiency of 
an altered RDS coupon system among PWID. Awareness of HIV infection was self-reported 
using an interviewer-administered questionnaire, which is subject to recall or reporting bias, 
though well-trained interviewers are used to mitigate bias. Validating self-reported diagnosis 
status with local testing centers in Morinda was not be feasible. However, incorporating HIV 
plasma viral load data, when available, can assess the number of individuals that are likely 
already diagnosed and on ART (i.e., have an undetectable viral load) but do not self-report being 
aware of their infection.  
 
In summary, getting to the UNAIDS 90-90-90 target will require novel strategies to reach the 
more hidden or difficult-to-reach people living with HIV (PLWH) that are not currently engaged 
in HIV testing and care services. RDS, already employed in HIV research and surveillance, 
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could be leveraged to reach undiagnosed PLWH, especially in key populations such as PWID 
and MSM who are stigmatized and often more difficult-to-reach populations that lag behind in 
the reaching the UNDAIDS target. While differential coupon distribution did not significantly 
increase the efficiency of identifying undiagnosed HIV-infected PWID, RDS or similar network-
driven strategies should still be considered alongside other strategies to ensure the UNAIDS first 
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Ratio 95% CI AUROC 95% CI VIMP 
n (col %)/ 
median (IQR) 
n (col %)/ 
median (IQR) 
Socio-demographics        


















0.56 - 0.99 
0.81 - 1.38 
0.95 - 1.59 
-- --  -- 
Age, years (model by 10 years) 28 (23 - 35) 29 (23 - 36) 1.06 0.96 - 1.17 0.499 0.471 - 0.527 -0.00499 
Female (model vs. male/hijra) 12 (0.3) 2 (0.4) 1.21 0.27 - 5.41 0.457 0.430 - 0.484 0.00002 
Marital status        
Never married 












0.69 - 1.03 
0.53 - 1.16 
0.495 0.468 - 0.523 -0.00189 
Education        
No/primary school 
Secondary school 











0.86 - 1.29 
0.62 - 1.13 
0.490 0.464 - 0.517 -0.00308 
HIV/HCV characteristics        
Tested for HIV in prior year 1180 (33.6) 166 (34.2) 1.07 0.88 - 1.31 0.495 0.467 - 0.523 -0.00133 
HIV positive 623 (17.7) 119 (24.5) 1.50 1.20 - 1.88 0.502 0.473 - 0.531 -- 
HIV status and diagnosis        
HIV negative 
HIV positive, undiagnosed 











1.12 - 1.88 
1.13 - 2.42 
0.502 0.474 - 0.531 -0.00125 
HIV status and viral load        
HIV negative 
HIV positive, undetectable 











0.58 - 2.21 
1.24 - 1.97 
0.497 0.468 - 0.526 -- 
HCV positive 1606 (45.7) 268 (55.1) 1.46 1.21 - 1.77 0.520 0.492 - 0.547 -- 













Ratio 95% CI AUROC 95% CI VIMP 
n (col %)/ 
median (IQR) 
n (col %)/ 
median (IQR) 
HIV and HCV negative 
HIV positive/HCV negative 
HIV negative/HCV positive 














0.89 - 2.45 
1.11 - 1.71 
1.37 - 2.31 
0.531 0.503 - 0.559 0.00049 
Sexual risk behaviors        
Lifetime sexual partners        
None 
1 or 2 
3 to 7 
8 to 17 

















0.57 - 1.02 
0.59 - 1.05 
0.45 - 0.94 
0.45 - 1.00 
0.500 0.472 - 0.527 -0.00012 
Sexual partners in prior 6 mo.        
None 
1 











0.68 - 1.03 
0.55 - 0.99 
0.509 0.482 - 0.536 -0.00175 
No sexual partners in prior 6 mo. 1698 (48.3) 261 (53.7) 1.24 1.03 - 1.50 0.506 0.479 - 0.534 -- 
Unprotected sex in prior 6 mo.        
No 
Yes 











0.70 - 1.32 
0.89 - 1.64 
0.500 0.472 - 0.527 -0.00019 
Substance use risk behaviors        














0.83 - 1.36 
0.62 - 1.00 
0.493 0.467 - 0.520 -0.00148 
Drugs ever injected        
Heroin only 











1.41 - 3.88 
1.08 - 3.05 
0.513 0.487 - 0.538 -0.00149 













Ratio 95% CI AUROC 95% CI VIMP 
n (col %)/ 
median (IQR) 
n (col %)/ 
median (IQR) 
None 












0.78 - 1.50 
0.85 - 1.58 
0.485 0.457 - 0.513 -0.00031 
Shared needle/syringe in prior 6 mo. 992 (28.2) 137 (28.2) 1.00 0.81 - 1.23 0.449 0.422 - 0.476 -0.00067 
Drugs injected in prior 6 mo.:        
Heroin 835 (23.8) 91 (18.7) 0.74 0.58 - 0.94 0.489 0.463 - 0.514 -0.00054 
Buprenorphine 2420 (68.8) 371 (76.3) 1.46 1.17 - 1.82 0.510 0.483 - 0.536 -0.00120 
Stimulants 15 (0.4) 3 (0.6) 1.45 0.42 - 5.03 * * 0.00013 
Sedatives 431 (12.3) 68 (14.0) 1.16 0.88 - 1.53 0.473 0.445 - 0.501 0.00064 
Place injected in prior 6 mo.:        
Home 752 (21.4) 95 (19.6) 0.89 0.70 - 1.13 0.478 0.451 - 0.505 -0.00031 
Friend’s house 752 (21.4) 94 (19.3) 0.88 0.69 - 1.12 0.482 0.455 - 0.508 0.00013 
Public park/playground 1809 (51.5) 238 (49.0) 0.91 0.75 - 1.09 0.486 0.459 - 0.513 -0.00041 
Public toilet 822 (23.4) 107 (22.0) 0.93 0.74 - 1.16 0.471 0.445 - 0.497 0.00004 
Shooting gallery 973 (27.7) 166 (34.2) 1.36 1.11 - 1.66 0.504 0.475 - 0.532 0.00086 
Graveyard, cemetery, burial ground 749 (21.3) 88 (18.1) 0.82 0.64 - 1.04 0.476 0.450 - 0.502 -0.00190 
Other place 956 (27.2) 107 (22.0) 0.76 0.60 - 0.95 0.487 0.460 - 0.513 0.00008 
Injected with in prior 6 mo.:        
Alone 1735 (49.4) 254 (52.3) 1.12 0.93 - 1.36 0.483 0.456 - 0.511 -0.00048 
Spouse/sexual partner 39 (1.1) 13 (2.7) 2.45 1.30 - 4.62 0.468 0.441 - 0.496 0.00018 
One other person 1503 (42.8) 203 (41.8) 0.96 0.79 - 1.16 0.474 0.447 - 0.501 -0.00048 
Multiple other persons 1272 (36.2) 186 (38.3) 1.09 0.90 - 1.33 0.463 0.435 - 0.490 0.00045 
Number of persons injected with in prior 30 
days 
       
None 
1 to 5 
6 to 10 














0.90 - 1.41 
0.65 - 1.28 
0.73 - 1.53 
0.481 0.454 - 0.509 -0.00262 
Needle/syringe exchange program use in prior 
6 mo. 
1464 (41.6) 255 (52.5) 1.55 1.28 - 1.87 0.522 0.494 - 0.550 0.00225 
Opioid agonist therapy in past 6 mo. 838 (23.8) 113 (23.3) 0.97 0.77 - 1.21 0.456 0.429 - 0.483 -0.00125 













Ratio 95% CI AUROC 95% CI VIMP 
n (col %)/ 
median (IQR) 
n (col %)/ 
median (IQR) 
Network size        
PWID network size† (model by one ln) 15 (6 - 40) 20 (8 - 50) 1.10 1.03 - 1.18 0.534 0.507 - 0.562 -0.00465 
PWID network size†         
10 or less 
11 to 20 
21 to 50 














1.01 - 1.70 
1.11 - 1.83 
1.11 - 1.93 
0.516 0.489 - 0.543 -- 
PWID: person who injects drugs; IQR: interquartile range; CI: confidence interval; AUROC: area under the receiver operator curve from univariable logistic model; VIMP: variable importance from 
random forest; HCV: Hepatitis C virus; ln: natural log 
*AUROC not calculable due to small number of observations in some cells; †Number of PWID they personally know in their city; --Characteristic not included in random forest. 
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Table 4.2 Multivariable models of recruiting an undiagnosed HIV-infected PWID and their predictive accuracy 
 
Model 1: Logistic predictors 
only 
Model 2: Random forest 
predictors only 
Model 3: Logistic and 
random forest predictors 
Characteristic 
Adjusted 
odds ratio 95% CI 
Adjusted 
odds ratio 95% CI 
Adjusted 
odds ratio 95% CI 
Female (reference=male/hijra) --  1.06 0.23 - 5.02 1.05 0.22 - 4.97 
HIV/HCV status       
HIV and HCV negative 
HIV positive/HCV negative 
HIV negative/HCV positive 






0.79 - 2.21 
0.99 - 1.57 





0.80 - 2.24 
1.04 - 1.65 





0.78 - 2.18 
0.98 - 1.56 
1.11 - 1.94 
Sexual partners in prior 6 mo.       
None 
1 





0.71 - 1.08 










0.70 - 1.07 
0.62 - 1.15 
Drugs ever injected       
Heroin only 






1.08 - 3.21 









1.03 - 3.12 
0.79 - 2.40 
Drugs injected in prior 6 mo.:       
Buprenorphine 1.00 0.77 - 1.30 -- -- 1.05 0.80 - 1.38 
Stimulants --  1.55 0.44 - 5.45 1.88 0.53 - 6.70 
Sedatives --  1.02 0.76 - 1.37 1.00 0.74 - 1.34 
Place injected in prior 6 mo.:       
Friend’s house --  0.84 0.65 - 1.08 0.89 0.69 - 1.15 
Public toilet --  0.89 0.70 - 1.12 0.91 0.72 - 1.16 
Shooting gallery 1.20 0.96 - 1.50 1.18 0.94 - 1.48 1.14 0.90 - 1.44 
Other place --  0.74 0.59 - 0.94 0.75 0.59 - 0.95 
Injected with in prior 6 mo.:       
Spouse/sexual partner --  2.39 1.25 - 4.58 2.44 1.27 - 4.66 
Multiple other persons --  1.12 0.91 - 1.37 1.10 0.89 - 1.35 
Needle/syringe exchange program use in prior 6 months 1.26 1.01 - 1.56 1.34 1.08 - 1.65 1.26 1.01 - 1.57 
Incarcerated in prior 6 mo. --  1.06 0.75 - 1.50 1.06 0.75 - 1.51 
PWID network size† (by increase in one ln) 1.09 1.02 - 1.17 -- -- 1.09 1.01 - 1.17 
AUROC 0.573 0.546 - 0.600 0.567 0.539 - 0.594 0.575 0.548 - 0.602 
PWID: people who inject drugs; CI: confidence interval; HCV: Hepatitis C virus; ln: natural log; AUROC: area under the receiver operator curve 
†Number of PWID they personally know in their city
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Table 4.3 Characteristics by RDS coupon system, recruits of each coupon system, and number of recruitment coupons received 
Characteristic  


























who received 5 
coupons 
(N=589) 
Age (years) 27 (22 - 33) 26 (22 - 34) 26 (23 - 33) 27 (22 - 33) 26 (22 - 34) 27 (23 - 33) 
Currently married 271 (42.2) 249 (38.5) 188 (39.6) 332 (41.0) 92 (41.6) 240 (40.8) 
Education       
No/primary school 
Secondary school 



















Tested for HIV in prior year 222 (34.5) 242 (37.5) 179 (37.7) 284 (35.1) 50 (22.6) 234 (39.7) 
HIV/HCV status       
HIV and HCV negative 
HIV positive/HCV negative 
HIV negative/HCV positive 

























Undiagnosed HIV infection (among all) 52 (8.1) 42 (6.5) 29 (6.1) 65 (8.0) 12 (5.4) 53 (9.0) 
Undiagnosed HIV infection (among HIV 
positives) 52 (70.3) 42 (61.8) 29 (65.9) 65 (67.7) 12 (70.6) 53 (67.1) 
Undiagnosed HCV infection (among HCV 
positives) 258 (89.0) 256 (89.2) 173 (89.2) 338 (89.2) 84 (88.4) 254 (89.4) 
Injection drug use frequency in prior 6 mo.       
None 




















Drugs injected in prior 6 mo. (among active 




































Shared needle/syringe in prior 6 mo. (among 
active injectors) 134 (26.2) 138 (27.1) 105 (27.4) 166 (26.1) 39 (23.4) 127 (27.1) 
Needle/syringe exchange program use in 
prior 6 mo. 228 (35.5) 216 (33.4) 162 (34.1) 278 (34.3) 62 (28.1) 216 (36.7) 
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Characteristic  


























who received 5 
coupons 
(N=589) 
Opioid agonist therapy in past 6 mo. 172 (26.8) 194 (30.0) 135 (28.4) 229 (28.3) 45 (20.4) 184 (31.2) 
Sexual partners in prior 6 mo.       
None 
1 



















Incarcerated in prior 6 mo. 8 (1.2) 17 (2.6) 10 (2.1) 14 (1.7) 2 (0.9) 12 (2.0) 
PWID network size†        
10 or less 
11 to 20 
21 to 50 

























RDS: respondent-driven sampling; IQR: interquartile range; HCV: Hepatitis C virus; PWID: people who inject drugs 






Supplementary Table 4.1 Recruit characteristics by recruiter’s RDS coupon system arm, among 
those with predicted high probability 
 
Characteristic  
n (column %)/ median (IQR) 






Recruits of altered 
system who 
received 5 coupons 
(N=589) 
Age (years) 26 (23 - 33) 27 (23 - 33) 
Currently married 94 (37.3)  240 (40.8) 
Education   
No/primary school 
Secondary school 







Tested for HIV in prior year 87 (34.5) 234 (39.7) 
HIV/HCV status   
HIV and HCV negative 
HIV positive/HCV negative 
HIV negative/HCV positive 









Undiagnosed HIV infection (among all) 20 (7.9) 53 (9.0) 
Undiagnosed HIV infection (among HIV positives) 20 (69.0) 53 (67.1) 
Undiagnosed HCV infection (among HCV positives) 89 (89.0) 254 (89.4) 
Injection drug use frequency in prior 6 mo.   
None 
























Shared needle/syringe in prior 6 mo. (among active injectors) 62 (30.7) 127 (27.1) 
Needle/syringe exchange program use in prior 6 mo. 84 (33.3) 216 (36.7) 
Opioid agonist therapy in past 6 mo. 65 (25.8) 184 (31.2) 
Sexual partners in prior 6 mo.   
None 
1 







Incarcerated in prior 6 mo. 6 (2.4) 12 (2.0) 
PWID network size†    
10 or less 
11 to 20 
21 to 50 









RDS: respondent-driven sampling; IQR: interquartile range; HCV: Hepatitis C virus; PWID: people who inject drugs 





Chapter 5: Discussion 
SUMMARY OF FINDINGS 
This work informs the utility and implementation of an intervention strategy using RDS that 
seeks to improve levels of diagnosis among HIV-infected PWID by first leveraging a large 
existing RDS data set from diverse regions of India and then, testing a novel RDS coupon system 
in a city in Punjab, India.  
 
In Chapter 2 (Aim 1), using data from over 14,000 unique persons in six Indian cities, we found 
RDS required screening fewer PWID and more rapidly identified undiagnosed HIV-infected 
PWID compared to ICCs (a venue-based strategy). The NNR - interpreted as the average number 
of PWID recruited/screened in order to find one undiagnosed HIV-infected PWID - for the ICC 
was 26.1 while for the RDS it was 10.9. Therefore, on average, RDS required screening 15 fewer 
PWID in order to identify one undiagnosed PWID compared to ICCs.  Across all six cities, ICCs 
identified 2.7 undiagnosed HIV-infected PWID per week while the RDS identified 18.6 per 
week. Therefore, on average, RDS identified nearly 16 more undiagnosed PWID each week 
compared to ICCs. Substantial differences in efficiency (i.e., NNR and identification rate) 
between RDS and ICCs were seen in all six cities individually, with the exception of the NNR in 
Bilaspur, in which RDS and the ICC results were similar.  
 
After accounting for suppressed HIV viral load among those self-reporting no prior diagnosis in 
the RDS, differences between the RDS and ICC in terms of efficiency persisted. After restricting 
to the first 1000 ICC clients to have comparable sample sizes between the RDS and ICC, 
significant differences in efficiency remained. Other comparative investigations of the ability of 
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RDS to identify undiagnosed PLWH from injecting and other vulnerable populations found 
mixed results; some found RDS to identify more while others found other strategies such as 
venue-based to be more efficient1-4. We also found population demographics varied across RDS 
and ICCs; men, those widowed/divorced/separated, and with higher education were more likely 
to be RDS participants than ICC clients. 
 
Looking at temporal trends in the NNR and identification rate, both were quite stable over the 
approximate 2-year time period in the ICCs. The NNR for RDS overall appears to increase over 
time, though this pattern was not consistent across all cities. The identification rate for RDS 
overall shows a sharp increase in the beginning and then a slow decrease over time, though, 
again, this pattern was not consistent across all cities. In Ludhiana, a city in north India, where 
we were able to map area of residence for PWID, data suggest that RDS reaches PWID that live 
farther from the RDS study site while ICC clients generally reside closer to the ICC in the central 
area of the city. The mean distance between an RDS participant’s pin code and the RDS site was 
higher (11.2km) compared to the mean distance for ICC clients (7.5 km) and those that were 
both ICC clients and RDS participants (9.2 km). 
 
In Chapter 3 (Aim 2), we explored the ability of ten easy-to-collect characteristics of PWID - 
socio-demographics, injection duration, sharing needles/syringes, NEP and OAT utilization, 
network size, and HIV and HCV status - to predict which individuals were most likely to know 
and recruit an undiagnosed/viremic PLWH into an RDS using data from 14,481 PWID RDS 
participants in 15 different Indian cities. HIV and HCV infection in addition to factors associated 
with higher HIV risk were most strongly associated with recruiting an undiagnosed and viremic 
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PLWH. Among PWID with HIV/HCV co-infection, a large network size (≥51), and that reported 
sharing needles/syringes in the prior six months, a quarter recruited at least one undiagnosed 
PLWH and a third recruited a viremic PLWH. Other researchers have found a similar 
recruitment pattern in terms of HIV status; HIV-infected RDS participants are more likely to 
recruit network members that are also HIV-infected5,6. 
 
A multivariable model with all ten characteristics was able to predict with moderate ability the 
recruitment of an undiagnosed (AUROC=0.67) and viremic (0.66) PLWH. A restricted model 
with only HIV/HCV status and network size was also moderately predictive (undiagnosed 
AUROC=0.64; viremic AUROC=0.65). When the full model was applied to different contexts 
across India, it performed best (i.e., higher AUROC) in areas with low harm reduction access. 
For recruitment of an undiagnosed PLWH, prediction was also higher in settings with low 
HIV/HCV services availability or accessibility as well as areas with emerging or ongoing 
epidemics (i.e., high HIV incidence). For recruitment of viremic PLWH, no HIV- or HCV-
related community-level characteristics were correlated with predictive ability.  
 
In Chapter 4 (Aim 3), among an RDS sample of 1289 PWID in Morinda, Punjab, an altered RDS 
coupon system in which individuals more likely to recruit undiagnosed HIV-infected PWID were 
provided more recruitment coupons did not significantly improve the efficiency of identification 
of undiagnosed PWID over the normal/traditional coupon system in which all participants 
receive the same number of coupons, regardless of characteristics. The NNR for the normal 
coupon system was 16.4 compared to an NNR of 12.5 for the altered system (difference=3.9, 
95% CI: -1.6 to 13.1). Characteristics such as HIV and HCV infection, PWID network size, 
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utilization of needle/syringe exchange programs, and the injection environment - where PWID 
and with whom they inject - were used to determine which individuals received more recruitment 
coupons.  
 
Notably, characteristics’ predictive ability was generally quite low, suggesting recruitment 
and/or the network composition of our target population did not have strong enough patterns to 
steer an RDS to more efficiently identify undiagnosed PWID. However, more coupons 
distributed throughout the local PWID network from the altered system did result in a higher 
absolute number of undiagnosed HIV-infected PWID each week compared to the normal system 
(1.7 vs. 0.8/week). There is scarce prior work on the effect of differential coupon distribution on 
steering an RDS sample to preferentially identify sub-groups of a population, such as those HIV-
infected, undiagnosed, viremic, with high-risk behaviors, etc. Increasing compensation for 
recruitment of specific types of individuals has seen mixed results7,8. 
 
PUBLIC HEALTH SIGNIFICANCE AND IMPLICATIONS 
Reaching the UNAIDS 90-90-90 target in order to bring an end to the HIV epidemic requires not 
only implementing evidence-based prevention and care interventions but also scaling these up to 
reach all people that need them and finding new strategies to make marked progress in the care 
continuum. Furthermore, addressing disparities among key populations so that they are not left 
behind is crucial to reach the UNAIDS target and ultimately see HIV incidence dramatically 
decrease worldwide9. Currently, PWID and other key populations, often the hardest to reach and 
engage, have not benefited to the same extent from improvements in HIV prevention and 
therapy. They frequently lag behind in the care continuum10 and are experiencing growing 
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epidemics across the globe. Outside of sub-Saharan Africa, key populations (including sex 
workers, MSM, PWID, transgender individuals, and sexual partners of key populations) 
accounted for 80% of new infections in 201511. Even within sub-Saharan Africa, a quarter of 
new infections were seen among key populations. Injection drug use is a major driver of HIV 
globally. PWID account for an estimated 30% of new infections outside of sub-Saharan Africa12. 
In India, PWID consistently experience a higher burden of HIV than the general population and 
other vulnerable populations (i.e., MSM and female sex workers)12 with sub-optimal progress 
along the care continuum, especially at diagnosis13. 
 
The findings of this dissertation highlight a potentially promising way to close the gap for PWID 
at diagnosis by utilizing RDS beyond its traditional purpose of gathering data on a representative 
sample. The higher efficiency of RDS in identifying undiagnosed HIV-infected PWID when 
compared to the ICCs was striking, despite ICCs being specifically designed to address the needs 
of PWID in a stigma- and discrimination-free environment and the use of peer outreach workers 
to visit hot spots to encourage PWID to attend the ICC. This finding underscores the importance 
and effectiveness of leveraging peer networks to reach and engage PLWH in order to address 
gaps in the care continuum. Some people will not be aware of the services at a venue-based 
approach like ICCs because of where/with whom they inject or being on the periphery of a 
network, for example, or some may be aware of the venue but simply not be motivated to utilize 
it. Peer connections, peer pressure - in a positive way, and modest monetary compensation, 
critical parts of RDS, reach and encourage those that do not visit places like ICCs. Specifically, 
results from this work show RDS reached HIV-infected PWID not actively engaged in HIV 
testing services provided either at ICCs or targeted interventions by the government of India. It 
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should be noted, however, that ideally, both approaches would be used to provide HIV 
prevention, care, and treatment. RDS can quickly identify individuals from the community but 
those uninfected need continued engagement with prevention services and those infected require 
lifelong care and treatment, services that a one-time RDS cannot provide. 
 
An in-depth exploration of RDS recruitment patterns showed that there were identifiable 
predictors of recruiting an undiagnosed HIV-infected PWID into the RDS, one of the strongest 
being HIV/HCV infection. Those infected with either HIV/HCV or both were more likely to 
recruit an undiagnosed PWID. While other prior research also found recruitment homophily by 
HIV-infection status, our findings indicate that PLWH may be connected to undiagnosed PLWH, 
a pattern that could be leveraged to reach undiagnosed persons. Additionally, the association 
with recruiter HCV infection is, to our knowledge, a new finding. Though HCV is seen in the 
general population, the burden is especially high among PWID, with more than 50% infected14. 
For individuals, HCV is a strong indicator of current or past high-risk injection behaviors or 
characteristics in addition to a predictor of being connected to others with high-risk behaviors or 
characteristics, thus those likely to be HIV-infected and undiagnosed.  
 
When the full prediction model of recruiting an undiagnosed HIV-infected PWID in Aim 2 was 
applied to different settings in India, results suggest that utilizing an RDS-based approach using 
HIV/HCV status and basic, easy-to-collect characteristics to identify more undiagnosed HIV-
infected PWID may be most appropriate for communities with growing HIV epidemics and low 
PWID-targeted harm reduction and HIV/HCV service utilization. If there is little prior 
information on the local epidemic and service utilization, an abbreviated RDS could be 
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conducted for at least 5-6 waves to characterize the epidemic and population in order to 
determine appropriateness of the predictive model for that particular setting. Additionally, results 
imply the model may not be easily applied for the purposes of identifying viremic PLWH, given 
the different compositions of viremic populations (i.e., undiagnosed, diagnosed but not linked to 
care/ART, and sub-optimal adherence to ART) in different communities. It is important to note 
that the predictive abilities of individual characteristics as well as the full model were lower than 
hypothesized. 
 
With detailed information on who recruits undiagnosed HIV-infected PWID into an RDS, the 
next important question is how to use this information to identify undiagnosed PWID more 
efficiently. There is very little prior research on steering an RDS to preferentially recruit a 
particular sub-group in a population and, to our knowledge, none that specifically use a data-
driven approach by first identifying patterns in RDS recruitment. In Morinda, we formally tested 
whether provision of more recruitment coupons to those more likely to recruit an undiagnosed 
HIV-infected PWID results in finding more undiagnosed PWID, using predictors identified from 
existing RDS data in the same region of India. The efficiency, measured in terms of the NNR, 
between the two systems was not significantly different, suggesting that in this setting, a typical 
RDS in which all individual receive the same number of coupons works just as well as a targeted 
system in identifying undiagnosed HIV-infected PWID. However, the absolute number of 
undiagnosed PWID identified by the altered system was more than twice the number identified 
by the normal system as a consequence of more than twice the number of PWID recruited in 
total via the altered system. In an urgent situation such as an outbreak, reaching as many 
individuals as possible as quickly as possible with HIV testing and counseling is critical. Our 
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results suggest that increasing the number of coupons could make the overall recruitment process 
more rapid with more undiagnosed HIV-infected PWID identified quickly. 
 
LIMITATIONS AND STRENGTHS 
There are several limitations to this work that should be noted. Diagnosis status among those 
HIV-infected was self-reported in all analyses using data collected via an interviewer-
administered questionnaire. Well-trained interviewers are used to mitigate recall or reporting bias 
but are unable to eliminate it entirely. Validating the diagnosis status for all those HIV-infected 
by checking records at local testing centers would be extremely resource and time intensive and 
require collecting personal identifiers from all participants. For RDS data collected in the NCA 
trial, viral load was available for all HIV-infected participants so it was possible to re-categorize 
those not self-reporting a prior diagnosis but with a suppressed viral load as diagnosed. 
Sensitivity analyses in Aim 1 after this re-categorization did not change overall inferences. 
However, corrections for any other scenario is not possible, such as reporting a prior diagnosis 
when they were truly not or not reporting a prior diagnosis when they truly were but were 
viremic. Correction using viral load was not possible for ICC clients since viral load is not 
standard of care and was not routinely collected from clients.  
 
Cities selected for the NCA trial were not a random selection of cities in India; rather cities were 
selected in discussion with NACO, India to represent different HIV and injection drug use 
epidemics and were generally large, metropolitan cities15. Therefore, findings may not reflect 
PWID in other regions or more rural areas of India not represented in the NCA trial. Relatedly, 
findings may not be transportable to other regions of the world, where PWID network dynamics, 
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HIV prevention services, and care continuum outcomes differ from what is observed in India. 
The altered RDS coupon system was tested in only one community. The effectiveness of this 
approach in identifying undiagnosed HIV-infected PWID should not be concluded by just one 
study in one location. Additionally, the true difference in NNR between the two coupon systems 
may be meaningful but small, requiring a larger sample size than was collected in Morinda.  
 
There are also several strengths to this body of work. First, the large amount of RDS data from 
diverse Indian settings collected as part of the NCA trial allowed for an in-depth exploration of 
recruitment patterns. More than 14,000 PWID were recruited for the baseline assessment of the 
trial, which is, to our knowledge, one of the largest samples collected using RDS, especially in 
an LMIC setting. Additionally, detailed socio-demographic, network, and risk behaviors and 
characteristics were collected via the study questionnaire and provided an opportunity for a 
thorough investigation of potential predictors of recruiting an undiagnosed HIV-infected PWID. 
Available data from RDS as well as the ICCs from the six intervention cities in the trial also 
permitted a within-city comparison of RDS and ICCs while identifying overlap between the two 
using biometric technology, removing any confounding by different population characteristics, 
environment, and service availability. 
 
While the findings should not be generalized to other settings or populations, the methods used 
to identify predictors of recruitment within an RDS (i.e., linking recruiters and their recruits then 
using logistic models and/or random forests to identify predictors) could easily be applied to 
other key populations in other regions of the world for which RDS is also a common method to 
recruit study participants (e.g., MSM, sex workers, transgender individuals) for HIV surveillance 
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and research purposes. The methods could also be extended to other outcomes, such as specific 
risk behaviors and other HIV care continuum outcomes - for example, recruitment of PWID that 
report sharing needles/syringes or HIV-infected PWID diagnosed but not currently on treatment.  
 
FUTURE DIRECTIONS 
Looking to future work, more research is needed to understand the benefit of RDS over venue-
based and other approaches, such as drop-in centers and peer outreach, in other key populations 
such as MSM and in additional settings outside India with different HIV epidemics. As 
mentioned earlier, venues such as ICCs or drop-in centers play an important role and should be 
utilized to the extent that they benefit their target population. Investigating a novel strategy that 
incorporates RDS into a venue-based approach would be an important line of research, 
optimizing the benefits of both approaches simultaneously. For example, an RDS with onsite 
HIV counseling and testing could be run out of a care center (or very close nearby), so that 
individuals could be linked to appropriate services immediately (i.e., same day), either risk 
reduction counseling and harm reduction for those HIV-uninfected or care and treatment services 
for those infected. This type of dual strategy could improve the overall reach and lead to a 
community-level decrease in risk behaviors and increase in utilization of HIV prevention, care, 
and treatment services, closing or narrowing the gaps in the care continuum.  
 
More research into RDS recruitment patterns among PWID is also warranted. It is unknown 
whether similar predictors of recruiting an undiagnosed HIV-infected PWID would be seen in 
populations in different settings such as high-resource settings (e.g., United States or Europe) or 
in areas with a generalized HIV epidemic (e.g., sub-Saharan Africa). Consistency across 
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different settings would allow for widespread utilization of the patterns and findings. It is 
reasonable to hypothesize that HIV and HCV infection would be strong predictors in other 
injecting populations but factors such harm reduction utilization and where and with whom they 
inject may not predict recruitment patterns in other areas. With the large amount of RDS data 
already collected from PWID and other key populations around the world for HIV surveillance 
and research, it would be fairly easy to use the existing data to explore recruitment patterns. 
 
Since the altered RDS coupon approach was tested in only one location, replicating this design or 
a similar design in multiple other settings would strengthen the evidence base for steering an 
RDS to identify more undiagnosed PWID using differential coupon distribution and guide the 
implementation of the approach. Since HIV/HCV infection independently were strong 
predictors, a simplified version of our targeted coupon approach using only HIV and HCV 
infection from onsite rapid tests would be a very interesting line of future research. In general, 
there is very little prior work on the effects of differential coupon distribution for enriching a 
sample with a specific sub-group, therefore, more research in this area is needed. Other RDS 
alteration strategies besides differential coupon distribution should also be explored further. 
More research on promising strategies, such as rapid sequential RDS16 or terminating 
recruitment chains after a specific number of waves if an individual in the sub-group of interest 
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